by Ron Melton, O.D., and Randall Thomas, O.D. Sponsored by
June 15, 2007
A Supplement to
Dear friends and colleagues,
Can you believe that optometrists write as many prescriptions for allergy medicines as
our surgical counterparts? Iťs true, and that is very exciting. When this statement comes
true for glaucoma meds, we will have truly arrived--and public health will be very well
served.
As a profession, we continue to season well. Our prescription-writing patterns continue
to demonstrate that, while still the junior partner, our growth rate is very strong. Patient
care and practice growth are inseparable, so as we do more to serve our patients, they
reciprocate by expanding our practices. Iťs a wonderful "win-win" scenario.
There is steady, albeit slow growth within the ophthalmic pharmaceutical pipeline. We
continue to long for new classes of compounds and new cures, but enduring patience
seems to be the order of the day. For the 2007 Clinical Guide to Ophthalmic Drugs, we
have new formulations of current allergy medicines, and a prostaglandin upgrade that we
will highlight. This year, we want to re-emphasize the combination drugs, as a masterful
understanding of these classes can be enormously helpful to many, many patients. We'll
also share some new insights to patient care enhancement which we think can further
optometric practice maturation.
Also in this edition, we have enclosed a couple of tear-out forms that we think will help
promote and improve O.D. communications with primary-care physicians--an extremely
important aspect of the patient care continuity.
We are deeply grateful to all of you who have shared with us your appreciation of this
drug guide. It makes it all worthwhile.
Our very best wishes to all of you,
Sincerely,
Randall Thomas, O.D., M.P.H. Ron Melton, O.D.
Educators in Primary Eye Care, L.L.C.
www.eyeupdate.com
Enhancing Patient Care:
The O.D.-M.D. Link . . . . . . . . 2A
Update on Diabetes
Mellitus . . . . . . . . . . . . . . . . 7A
Antibiotics . . . . . . . . . . . . . . 9A
Corticosteroids . . . . . . . . . 16A
Clinical Cases for
Combination Drugs . . . . . . 22A
Allergy Drugs . . . . . . . . . . . 30A
Glaucoma Drugs . . . . . . . . 38A
AMD Update . . . . . . . . . . . . 40A
The Dysfunctional
Tear Film . . . . . . . . . . . . . . 42A
Clinical Pearls in
Patient Care . . . . . . . . . . . . 46A
Pediatric Pearls . . . . . . . . . 54A
REVIEW OF OPTOMETRY JUNE 15, 2007 1A
INTRODUCTION
CONTENTS
Call for Clinical Conundrums
Got a problematic patient?
Having difficulty determining a
diagnosis? Can't come to a
conclusion on a course of
therapy?
Send your clinical questions to
Drs. Melton & Thomas at:
DrugGuide@jobson.com.
They'll publish your question
--and their answer--in next
year's Clinical Guide to
Ophthalmic Drugs.
Sponsored by
REVIEW OF OPTOMETRY JUNE 15, 20072A
W
e just returned from a
conference where a family
doctor, whose
brother was an O.D., attended our
lectures. He told us he would like to
work more closely with the O.D.s
in his service area, especially with
regard to his patients with diabetes,
but he had become frustrated and
discouraged with the near-nonexistent
O.D. to M.D. communication.
Furthermore, he said he was very
willing to send all sorts of eye problems
to O.D.s in his city, but only
one optometrist had approached
him to establish a mutually beneficial
relationship to address patient
care. On the other hand, three different
area ophthalmologists take
him to professional ball games,
golf, dinner, etc., from time to time.
Is there any intelligent reason we
do not pursue these beneficial relationships
with other health-care
providers?
It gets worse. A rheumatologist
in our area has a brother who is an
O.D. in another state. When this
doctor first established his practice,
he gladly recommended that his
patients see their O.D. for Plaquenil
evaluations; but, after a year of a
frustrating lack of communication
from the O.D.s in the community,
he now steers his patients to area
ophthalmologists who consistently
communicate their findings to the
referring/prescribing M.D. How sad
is this?
Now, leťs be realistic. Optometry
is a foreign entity to the medical
community at large. In medical
school and residency training, all
eye and vision problems are handled
by ophthalmology. When these
new physicians enter our cities,
towns and communities, they
encounter a whole new breed of
provider with whom they are not
familiar: the optometric
physician. These new
M.D.s do seem to understand
that O.D.s "fit eyeglasses
and contact
lenses," but they have no
idea of the scope of
training and clinical
competence we O.D.s
can provide.
For example, we
encountered a family
physician at a function
recently. He recounted to
us how his wife and
daughter, "just love their
optometrist." He, however,
had never sent any
of his diabetic patients to
that O.D. Why? Because
he was completely
unaware that O.D.s performed
diabetic eye evaluations!
We were
delighted to have the
opportunity to educate this physician
about our profession, and he
was equally delighted to know that
he could start sending his patients
with diabetes (and other medical
eye needs) to his family's optom-
etrist.
We don't know what percentage
of primary-care physicians would
be willing to partner with an O.D.,
and it really doesn't matter. What
does matter is that we, as a profesENHANCING
PATIENT
CARE: THE OD-MD LINK
ENHANCING PATIENT
CARE: THE OD-MD LINK
Some family physicians and other M.D.s have no idea of the scope of optometric
training and care. To change this, we must communicate with these doctors.
For the sake of your patients and the sake of your
practice, start working with your local physicians.
REVIEW OF OPTOMETRY JUNE 15, 2007 3A
OD-MD Communication
sion, need to begin to step out of
our little boxes and interact with
the medical community--first, to
complement and enhance patient
care; and second, to grow our prac-
tices.
Established physicians have
established referral relationships
that are very difficult to alter
(although that does not mean we
shouldn't try). However, when new
physicians come to town, take the
initiative and invite them to lunch,
preferably within their first month;
some will eagerly accept, while others
may not. The result may be very
rewarding, or it may be disappointing.
One thing is certain: nothing
ventured, nothing gained.
Written communication with
doctors in the community can be
technologically challenging. In our
practices, we contract with a local
medical transcription service to type
our letters. The service's dictation/
transcription system allows us to
simply dial a local or toll-free telephone
number from any phone and
give our verbal dictation. The service
then transcribes our dictation
and returns the drafts to our office
via a secure site. The letters are
either printed out for our review, or
we can review them on screen, and
make any necessary changes. Our
staff prints the letters out on our
letterhead, we sign them, and they
are mailed. Copies are generated for
the patient charts. There are lots of
medical transcription services out
there. Bottom line: Call your personal
physician, any medical specialist,
or an ophthalmologist to
find out how their correspondence
is handled; find a reliable service
and get onboard.
We generate letters on all our
patients with medical problems to
their referring physicians, except
when a patient is referred for a diabetic
eye or Plaquenil evaluation. In
those instances, we simply fill out
an in-house form that takes perhaps
20 to 30 seconds to complete. We
then fax these forms to the referring
doctors, and place the originals in
the patient charts. These forms save
us both time and the cost of a
postage stamp. We have included
the Plaquenil form (page 5) and the
diabetes form (page 6) that we use.
Please feel free to use them "as is,"
Examples of Letters to Referring Physicians
Remember, be concise and to the point. Notice that there are no refraction numbers
because they are meaningless to physicians. Speak their language.
EXAMPLE LETTER ON ADENOVIRAL INFECTION
Dear Doctor,
Ms. Rickard has been a long-time patient in our office. She developed red eyes about a
week and a half ago, and has been using an eye drop for the past several days given to
her by you. However, Ms. Rickard could not recall the name of the drop. When her eye
redness had not resolved within the expected period of time, you sent her here for con-
sultation.
Ms. Rickarďs entering visual acuity was 20/30 right eye and 20/50 left eye with her
eyeglasses. Both eyes were Grade 1 injected. There were no palpable preauricular lymph
nodes. Her corneas were clear with no fluorescein staining. She did give a history of a
mostly watery discharge during the course of her problem. Her anterior chambers were
deep and clear. Eyelid eversion was normal in both eyes.
It is my impression that Ms. Rickard is at the tail end of a low virulence expression of
an adenoviral infection. I placed her on Alrex Ophthalmic Suspension to be used QID x 1
week. Alrex is a moderate-strength, topical corticosteroid. I anticipate that Ms. Rickard
will do fine and have no sequelae to her probable adenoviral infection.
Thank you for sending Ms. Rickard over for consultation. If I can be of any further help
to you in any way, please do not hesitate to call.
Sincerely,
EXAMPLE LETTER ON MACULAR DEGENERATION
Dear Doctor,
This is my fourth time to see Mr. Jones in the office. As you know, he is taking deferoxamine
3 to 4 times weekly for his liver treatment.
Mr. Jones is correctable to 20/25 right eye and 20/20 left eye. He maintains an icteric
sclera. His slit lamp examination is entirely normal. Ophthalmoscopic examination reveals
healthy optic nerves with a 0.1 cup in each optic nerve head. There is some mild, geographic
atrophic macular degeneration in the right eye, and a rough textured appearance
to the macula in the left eye. Although uncommon at the young age of 47, this does not
appear to be anything associated with the deferoxamine therapy. His visual field testing is
nearly normal in both eyes. There is no evidence of any type of optic neuropathy associated
with the deferoxamine. I have updated Mr. Jones's eyeglasses and have asked to see
him back on an annual basis.
I trust this information is helpful to you. I wish you well in your overall care of this nice
gentleman.
Sincerely,
(conťd on next page)
REVIEW OF OPTOMETRY JUNE 15, 20074A
or make any changes that you feel
will enhance their usefulness to you
in your service to your patients.
You can also download these forms
from our web site www.eyeupdate.
com.
A note about letters: Be direct
and succinct. All that a primarycare
physician wants to know is the
essentials--nothing more. This is a
real pearl, and it needs to be
heeded. In general, PCPs know little
about the eye. Keep the language in
your letter clear, basic, and to the
point.
Here, we have selected some
actual letters that we have written
to help give you a flavor for the
character such letters should take.
(Names of doctors and patients in
these letters are fictitious.)
We, as a profession, possess a
tremendous knowledge base. We
have the ability to perform a scope
of professional services for our
patients that go far beyond refractive
care. Unfortunately, it seems
this is a well-kept secret that we are
not even sharing with our own
patients, let alone their physicians!
Surely, we all know optometric
physicians who have prosperous,
diverse and thriving practices. Ask
yourself, "What are these doctors
doing that I'm not?" You'll likely
find that they have put in the time
and effort to actively engage and
educate their patients about the
services and expertise they offer.
They have labored to build and
maintain strong relationships with
other physicians in their community,
and to keep the lines of communication
open with their referral
sources. In other words, they are
their own best advocate.
The opportunity for you to do
likewise is there. If you aren't satisfied
with the number or types of
patients you are seeing, YOU are
the only one who can change that.
Lunches and letters are a good
start. 
EXAMPLE LETTER ON ORDERING LABS
Dear Doctor,
I have been seeing Ms. Rainski in the office since November 1997. She has a history of
recurrent episcleritis. At her most recent visit, she expressed some concern as to the
underlying etiology of this recurrent problem. She has no history of lupus or gout. It was
felt, however, that a systemic evaluation was in order. In the meantime, I have treated her
with Lotemax (a potent, topical ophthalmic corticosteroid) every two hours for several
days, and then QID x 1 week. When Ms. Rainski returned in one week, she was 90%
improved.
Ms. Rainski does have some mild arthritis, malaise, and some general achiness. We
ordered a CBC, sed rate, ANA, anti-DNA, RF, and TSH. As you can see from the enclosed
copies of this focused workup, her only positive test is a smooth pattern ANA at a ratio of
1:60. I am surprised that the ANA was positive, and yet the anti-DNA was negative. I am
sure you can explain that better than I.
I want to make you aware of this information since you are Ms. Rainski's primary care
physician. I trust this information is helpful to you. If you have any information on your
end that you feel would be helpful to me in my portion of her care, I would appreciate you
passing it along. I do wish you well in your overall care of this nice lady.
Sincerely,
EXAMPLE LETTER ON CHRONIC BLEPHARITIS
Dear Doctor,
I saw Mr. Rink in our office April 1, 2004 upon your referral. He complained of having a
flare-up of a red, painful right eye for the past several days. He complains of having this
problem occur about every six months for the past ten years. Mr. Rink has used an antibiotic/steroid
eyedrop off and on for years for this condition.
Mr. Rink's slit lamp examination reveals a classic, peripheral, sterile corneal ulcer secondary
to staphylococcal exotoxin erosion of the superficial epithelial tissues. He has lowgrade
staphylococcal blepharitis in the right eye, as well. The left eye appears to be nor-
mal.
I explained to Mr. Rink the underlying problem is his chronic blepharitis and instructed
him in how to properly, carefully, and meticulously keep his eyelids as clean as is humanly
possible. If we can keep Mr. Rink's lids clean, and can decrease the population of the
staphylococcal bacteria on his eyelid margins, I think we will be able to prevent, or at
least minimize, recurrent toxic erosion to his peripheral cornea. I prescribed Zylet (a
newer combination antibiotic/steroid eyedrop) to use three or four times a day as needed.
In addition, I have placed him on Polysporin Ophthalmic Ointment at bedtime for the next
two to three weeks in an attempt to diminish resident eyelid staph.
I thank you for your kindness in sending Mr. Rink for consultation. I trust this information
is helpful to you, and wish you well in your overall care of this nice man.
Sincerely,
OD-MD Communication
SAVE TIME -- SNIP THIS!
Clip out these forms, affix
your letterhead, or use "as
is." Fill it out and fax to the
referring physician.
PLAQUENIL EYE EVALUATION REPORT
Date
Patient Name DOB
Prescribing Doctor Fax #
Consulting Optometrist
Plaquenil dose mg Patienťs weight
Visual acuity: right eye 20/ left eye 20/
Slit lamp exam: Normal Other
Fundus exam: Normal Other
Macular Visual field Testing (10-2): Normal Other
Recheck: 1 year Other
Comments:
Thank you very much for entrusting your patients to us for their eye care.
DIABETIC EYE EVALUATION REPORT
Date
Patient Name DOB
Primary Care Provider Fax #
Endocrinologist Fax #
Consultant Optometrist
Duration of Known Diabetes
Most recent A1c % A1c unknown by patient
Visual acuity: right eye 20/ left eye 20/
Slit lamp exam: Normal Other
Dilated fundus exam:
No diabetic retinopathy right eye left eye
Other findings:
Recheck: Annually Other
Comments:
Thank you very much for entrusting your patients to us for their eye care.
REVIEW OF OPTOMETRY JUNE 15, 2007 7A
Diabetes
* Definition: fasting plasma glucose greater than 126mg/dl.
* 5% to 10% of diabetic patients have Type I diabetes mellitus
(insulin-dependent).
* 90% to 95% of diabetic patients have Type II diabetes mellitus
(treated with oral medicines, and occasionally with insulin also).
* Approximately 15 to 18 million Americans have diabetes, and
about 250,000 of these people are under age 20.
* Native peoples are disproportionately afflicted.
* Risk factors for development or progression of diabetic retinopa-
thy:
­ Severity of hyperglycemia
­ Duration of diabetes
­ Systemic hypertension
­ Hyperlipidemia
* After retinopathy is present, the severity of hyperglycemia, rather
than duration of diabetes, seems to confer greater risk for pro-
gression.
* Intensive control of blood glucose is associated with a muchdecreased
risk for retinopathy and other complications.
* Based on the Wisconsin Epidemiology Study of Diabetic Retinopathy,
patients with Type I diabetes will express retinopathy at an
approximate rate of 25% after five years, 60% after 10 years, and
80% after 15 years. As many as 25% of these diabetic patients
will have proliferative diabetic retinopathy.
* In the same Wisconsin study, Type II patients expressed retinopathy
somewhat similarly, but those controlled without the need
for insulin unsurprisingly fared better than those requiring the
addition of insulin. Bottom line: There is a direct relationship
between the duration of diabetes and the incidence of retinopathy.
* Development of hemorrhages and exudates occurs 50% faster
when cholesterol and/or triglyceride levels are above normal.
* Intensive treatment and control of glycemic levels in Type I
patients reduces the risk of developing retinopathy by about 75%
and slows progression of established retinopathy by about 50%.
* Similar intensive control in Type 2 patients reduces the risk of
developing retinopathy by about 25%, and a similar reduction in
risk was achieved by keeping blood pressure below 150/85.
* The number of patients referred by their primary-care physician
for ophthalmic care (only 34% to 65%) is far below consensus
expert guidelines. (We urge all O.D.s to work vigorously to develop
relationships with primary-care physicians in an effort to address
this major shortcoming.)
* When should patients with diabetes have their first diabetes-oriented
eye examination?
­ Type I: within five years of the diagnosis.
­ Type II: at the time of diagnosis, because the time of onset is
difficult to determine and may precede the diagnosis by a
number of years.
* Pregnancy: Diabetes mellitus is legendary for progression during
pregnancy in some patients. Therefore, all diabetic pregnant
patients should be examined close to the time of conception. A
second examination should be performed during the first trimester.
Another examination is needed if retinopathy was detected, or had
progressed on the initial or first trimester visit. These standards
hold true for all expecting diabetic patients, whether their diabetes
is Type I or Type II.
* Clinically significant diabetic macular edema (CSME) is a clinical
diagnosis, but can be assessed via OCT. Fluorescein angiography
is usually not needed, but can help guide laser therapy in the setting
of CSME.
* International Clinical Classification of Diabetic Retinopathy
(ICCDR):
­ Mild nonproliferative diabetic retinopathy: microaneurysms
only.
­ Moderate nonproliferative diabetic retinopathy: more than
microaneurysms, but less than severe nonproliferative diabetic
retinopathy.
­ Severe nonproliferative diabetic retinopathy, which may
include any of the following:
 more than 20 intraretinal hemorrhages in each of four
quadrants
 definite venous beading in two or more quadrants
 prominent IRMA (intraretinal microvascular abnormalities)
in one or more quadrants.
­ Proliferative diabetic retinopathy, which is diagnosed when
one or both of the following is present:
 neovascularization
 vitreal or preretinal hemorrhage
* Regarding diabetic macular edema (DME), it is a clinical diagnosis,
made with biomicroscopic ophthalmoscopy. The OCT very eloquently
quantifies the degree of macular thickness as altered by
the macular edema. The clinical significance of DME is largely dictated
by the proximity of hard exudates to the center of the
macula.
Background diabetic retinopathy with macular involvement.
Update on Diabetes Mellitus1
ˇ Regarding the laser treatment of CSDME, the main goal and outcome
is "preventing moderate vision loss rather than improving
vision, although in some cases vision can improve." It is focal/grid
laser application that is applied to the edematous macular tissue
(as opposed to panretinal photocoagulation).
* It is recommended that eye doctors "educate all patients about
diabetes and stress the value of controlling blood glucose (measured
by hemoglobin A1c) as well as blood pressure control."
Be a Part of the Diabetic Care Team
Of all parameters of diabetic care, by far the greatest shortfall is
the recommended annual dilated eye examination. This begs the
questions: Are the patients not receiving timely eye care? Or, are
the provider optometrists not communicating their findings back to
the primary-care physician and/or endocrinologist?
The answer is probably "yes" to both questions. As O.D.s, we
have little control over the first part of the problem; however, we
can immediately rectify the second. We, as a profession, have an
ethical and moral imperative to enter into the mainstream of the
team approach to diabetic patient care by apprising the primarycare
physician of our mutual patients' eye status. This is easily
accomplished via a "Diabetic Eye Evaluation Form," which can be
filled out in approximately 30 seconds. (See page 6, or visit our
web site, www.eyeupdate.com, to download the form, affix to your
letterhead, and use for this purpose.) The form can then be faxed
to the appropriate physician(s).
One major hesitation to such communication by many
optometrists is the fear of encountering the following scenario:
[Primary-Care Physician:] "Mrs. Jones, I notice that you are
seeing an optometrist for your eye care. These `people' are not
medically trained. Since you have diabetes, I want you to start
seeing an ophthalmologist."
Thus, optometrists hesitate to communicate with primary-care
physicians due to the fear of perhaps encountering prejudice on
the part of some M.D.s who may refer the diabetic eye patient to
an ophthalmologist for ongoing care. Some medical doctors view
optometrists as practitioners "trained to fit eyeglasses," not realizing
(or recognizing) that O.D.s are thoroughly trained and capable
in the care not only of the diabetic eye, but most eye diseases.
The key to avoid the loss of your patient (and still communicate
important information about patients' ocular status with the primary
care physician) is proactive education on two levels. First,
educate your patients. Be sure they understand that you are a
doctor, trained and competent in diabetic eye care. If your patient
sees a primary-care physician with whom you do not yet have a
professional relationship, you might forewarn that the PCP may
attempt to send him/her to another eye doctor. Reassure the
patient that you have the expertise needed to follow him/her for
eye problems associated with diabetes.
It is equally important, if not more so, to at least attempt to educate
other members of your medical community about the scope
of professional care you can offer. Develop a practice information
packet and send it along to the primary-care physician with your
examination findings; place a phone call to the office and invite
the physician to lunch so you can become acquainted. This is
especially fruitful with newer physicians who have not already
established referral networks. Remember, most doctors (and many
of our patients) are under the impression that optometrists "only fit
eyeglasses and contact lenses." This is a serious under-representation
of our scope of professional services and it can be a drawback
for our patients--but iťs a situation we can easily correct if
we have the will and the perseverance.
1. Update on Diabetes and Eye Care 2006. National Eye Institute and Duke University.
Quality Reporting Guidelines for Diabetic Retinopathy
The 2007 Physician Quality Reporting Initiative (PQRI) guidelines can be seen at www.cms.hhs.gov/PQRI. These 74 unique guidelines,
issued by the Centers for Medicare and Medicaid Services (CMS), cover all elements of medical care. The stated goal for these guidelines
is to achieve the clinical standards outlined therein 80% of the time. Two of these standards are critical to the care of patients with diabetes
mellitus:
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus
exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema
during one or more office visits within 12 months.
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
Description: Percentage of patients aged 18 years or older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus
exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes regarding
the findings of the macular or fundus exam at least once within 12 months. (Emphasis added.)
As can be seen, continuity of care can be greatly enhanced when primary-care providers have meaningful feedback from specialtycare
providers, notably O.D.s.
Diabetes
REVIEW OF OPTOMETRY JUNE 15, 20078A
REVIEW OF OPTOMETRY JUNE 15, 2007 9A
Rather than prescribing an antiobiotic that will "do no harm" in a red eye, nail the
diagnosis first, then prescribe with precision.
E
verybody loves antibiotics.
They are considered a cureall
for most medical maladies,
but they aren't. Parents
commonly prevail upon the doctor
to give their child an antibiotic,
even though the condition is viral.
Even more common is the doctor
(eye or other) who is unsure of the
diagnosis, and therefore prescribes
an antibiotic because "it will do no
harm," in hopes that the condition
(whatever it is) will improve with
time.
Iťs frustrating that topical antibiotics
are still heavily prescribed.
This is particularly poignant as
their only clinical indication is bacterial
infection, one of the least
common entities we encounter in
clinical practice. Such infections are
more common in children than in
adults.
The reality is that the "red eye"
almost always represents some sort
of inflammatory condition, thus
calling for a topical corticosteroid,
or at least an antibiotic-steroid
combination.
The most common indication for
writing an antibiotic prescription is
for a patient presenting with acute
mucopurulent discharge. An
absolute indication for antibiotic
use is in patients with microbial
keratitis, although such presentations
are thankfully rare.
It must be stressed that most presumed
"corneal ulcers" are nothing
more than sterile leukocytic infiltrates
that usually merit a combination
product such as Zylet or
TobraDex--or generic Maxitrol, if
cost is an issue.
Not knowing the diagnosis is
poor justification to write for an
antibiotic. Red eyes are either infectious
or inflammatory, and inflammation
is by far the more common
presentation. If the cornea is not
compromised, and there is no
mucopurulence, then a steroid (or
even a combination drug) would be
an approach far more likely to benefit
the patient.
That said, leťs now characterize
the various antibacterial drugs with
the goal of optimum selection.
Sodium Sulfacetamide
Bacteria synthesize folic acid
from para-aminobenzoic acid, or
PABA. Folic acid is a necessary
component for normal cell physiol-
ogy.
Sulfa drugs, which are bacteriostatic,
inhibit this production of
folic acid. Because sulfa drugs are
chemically similar to PABA, com-
ANTIBIOTICSANTIBIOTICS
Anti biotics
The evident mucopurulent discharge is
pathognomic for bacterial conjunctivitis.
In contradistinction to the eye at left,
the injection pattern in the eye above
shows considerable hyperemia in the
paralimbal region, with relative sparing
of the forniceal conjunctiva. This patient
has advanced iridocyclitis.
Although not always consistent, such a
relative limbal-sparing conjunctival
injection pattern is common to bacterial
conjunctivitis.
REVIEW OF OPTOMETRY JUNE 15, 200710A
petitive inhibition of folic acid production
occurs, resulting in bacterial
death.
Though sulfas are broad-spectrum
drugs, a high percentage of
commonly encountered staphylococcal
organisms are resistant, as
are most Pseudomonas species.
Sulfas do not work well against
infections that produce copious
amounts of purulent exudate,
probably because there is much
PABA in these discharges, which
tends to negate the drug's mechanism
of PABA competition. Also,
many patients are allergic to sulfa
drugs.
For these reasons, sulfa drugs,
once a mainstay of treatment, are
now very poor choices. Much more
effective are Polytrim, tobramycin
or a fluoroquinolone.
The one exception is childhood
bacterial infection when the child
will not cooperate with eye drop
therapy. Most childhood bacterial
infections are caused by Streptococcus
pneumoniae or Haemophilus
influenzae, and 10% sodium
sulfacetamide may not be effective
against it. This is why Polytrim
remains our choice for children
who will accept eye drops.
Sodium sulfacetamide is available
in solution (10%, 15%, and 30%)
and ointment (10%). It is marketed
by numerous companies. The 30%
solution stings sharply on instillation
and is rarely used.
There are times when a patient is
seen for a very mild or self-limiting
conjunctivitis and you sense the
patient desires to be treated rather
than simply reassured. Because the
sulfa drugs are generic, inexpensive
and sting upon instillation, they can
serve as virtual placebo therapy in
such cases.
Bacitracin
This drug, which is bactericidal,
works by destroying
cell walls. Its antimicrobial
spectrum of activity is similar
to erythromycin, but
has greater activity against
most gram-positive bacteria.
Its effectiveness and
low likelihood of provoking
toxic or allergic reactions
would make it a drug
of choice for treating grampositive
bacteria, except that it is
only available as an ophthalmic
ointment. We do recommend its use
for the first week or two in treating
moderate to advanced cases of
staphylococcal blepharitis in addition
to providing aggressive eyelid
hygiene. Its only practical use, in
our opinion, is in select cases of blepharitis
management. It is generically
available.
Although bacitracin has been
around since 1943, it maintains
excellent activity against a host of
gram-positive organisms, including
methicillin-resistant Staphylococcus
aureus (MRSA). An article in
Apriľs American Journal of Ophthalmology
states: "For patients
exposed to healthcare facilities who
are at higher risk of infection from
nosocomial MRSA, we recommend
... considering a fourth-generation
fluoroquinolone or bacitracin for
preoperative prophylaxis."1
Bacitracin and Polymyxin B
This is an excellent broad-spectrum
antibiotic combination that
enjoys widespread use in eye care.
As bacitracin is highly effective
against gram-positive organisms,
polymyxin B is a potent killer of
gram-negative bacteria, including
Pseudomonas. It works by destroying
the cell membrane's structural
and functional integrity, resulting in
cell death. Resistance, toxicity and
allergic reactions are rare.
Not all patients with bacterial infection present with obvious mucopurulence. Careful
examination of the lacrimal lake, which is normally optically empty, may reveal
hundreds of microparticulant discharge/debris particles. This can help seal the
diagnosis.
The Enduring Value of Generics
When an ophthalmic drug becomes generic (i.e., loses patent protection), all marketing
promotion ceases. Of course, the drug remains as viable as ever, but with the absence of
samples and active promotion, it generally withdraws into the recesses of our brains.
However, one point that merits explanation is the enduring value of many generic drugs.
Drugs such as bacitracin, polymyxin B, and the aminoglycosides are like the Energizer
Bunny--they just keep going and going.
The explanation for this is very straightforward; they are not used systemically for a
variety of reasons. Any antibiotic used orally will ultimately develop resistance. Since the
above-mentioned antibiotics are not used systemically, they remain very viable for topical
ophthalmic use.
REVIEW OF OPTOMETRY JUNE 15, 2007 11A
Anti biotics
Doctors can use this drug
safely in most bacterial infections.
In blepharitis therapy,
since polymyxin B is nontoxic,
Polysporin can be substituted
for bacitracin should
the pharmacy not have
bacitracin. Unfortunately, it
is only available in the U.S.
as an ointment, which limits
its practical use in adults.
It is marketed as Polysporin ophthalmic
ointment by Monarch
Pharmaceuticals and numerous
generic manufacturers. Interestingly,
Polysporin ophthalmic solution is
available in Canada.
Bacitracin, Polymyxin B and
Neomycin
This is a very effective combination
antibiotic available both as
solution and ointment. The characteristics
of bacitracin and polymyxin
B are covered above. Neomycin,
an aminoglycoside, kills a broad
spectrum of bacteria by inhibiting
protein synthesis. It is effective
against most gram-positive and
gram-negative bacteria, with the
notable exception of Pseudomonas.
This preparation's Achilles' heel
is its potential for toxicity. About
8% of all patients experience a
delayed, type IV hypersensitivity
reaction to neomycin. If the
patient has not been
exposed to the drug before,
the reaction can occur within
five to ten days after therapy
has been initiated. If the
patient has been previously
sensitized, the reaction can
happen more quickly, usually
within 12 to 72 hours.
If such a classic
neomycin hypersensitivity
reaction were to occur, you would
usually see erythema and mild
edema of the eyelids, conjunctival
injection, and possibly superficial
punctate keratitis. The reaction usually
is most pronounced in the
inferonasal region of the eye,
because gravity and blinking concentrates
the drug there. The treatment
is to discontinue the drug.
The reaction typically resolves on
its own within a few days. Consider
prescribing cold compresses and/or
mild topical steroids, such as Alrex,
for two to four days.
Bacitracin (or gramicidin) with
polymyxin B and neomycin is
available as Neosporin from
Monarch Pharmaceuticals, and
generically. Neosporin is basically
Polysporin plus
neomycin, except that Neosporin
is available as a solution
and an ointment. In the
solution, gramicidin replaces
bacitracin, since bacitracin is
unstable in water. In terms of
activity, gramicidin is virtually identical
to bacitracin, but is more
water soluble.
Because newer antibiotics are
now available that are less toxic
and equally or superiorly efficacious,
Neosporin is rarely used.
Topical Antibiotic Drugs
BRAND NAME GENERIC NAME MANUFACTURER PREPARATION PEDIATRIC USE BOTTLE/TUBE
Fluoroquinolones
Ciloxan, and generic ciprofloxacin 0.3% Alcon, and generic sol./ung. > 1 yr./ > 2 yrs. 2.5ml, 5ml, 10ml/3.5g
Ocuflox, and generic ofloxacin 0.3% Allergan, and generic solution > 1 yr. 5ml, 10ml
Quixin levofloxacin 0.5% Vistakon Pharm. solution > 1 yr. 2.5ml, 5ml
Vigamox moxifloxacin 0.5% Alcon solution > 1 yr. 3ml
Zymar gatifloxacin 0.3% Allergan solution > 1 yr. 2.5ml, 5ml
Aminoglycosides
Tobrex, and generic tobramycin 0.3% Alcon, and generic sol./ung. > 2 mos. 5ml/3.5g
Genoptic, and generic gentamicin 0.3% Allergan, and generic sol./ung. N/A 1ml, 5ml
Polymyxin B Combinations
Polytrim polymyxin B/trimethoprim Allergan, and generic solution > 2 mos. 10ml
Polysporin polymyxin B/bacitracin Monarch, and generic unguent N/A 3.5g
Neosporin polymyxin B/neomycin/ Monarch, and generic sol/.ung. N/A 10ml/3.5g
gramicidin
Other Antibiotics
AzaSite azithromycin 1% Inspire Pharm. solution > 1 yr. 2.5ml
Ilotycin, and generic erythromycin 0.5% Dista, and generic unguent > 2 mos. 3.5g
AK-Tracin, and generic bacitracin 500u/g Akorn, and generic unguent N/A 3.5g, 3.75g
REVIEW OF OPTOMETRY JUNE 15, 200712A
Trimethoprim with Polymyxin B
Trimethoprim, a diaminopyrimidine,
achieves bacteriostasis by interfering with
folic acid production, but later in the
pathway than sulfa drugs. Specifically, it
interrupts the synthesis of tetrahydrofolic
acid, the metabolically usable form
of folic acid.
Trimethoprim is active against most
common gram-positive and gram-negative ocular
pathogens. It is inactive against Pseudomonas, which is
why polymyxin B is added to trimethoprim. Since
Streptococcus pneumoniae and Haemophilus influenzae
are common pathogens in children, this drug is an
excellent pediatric choice. To wit, pediatricians are the
largest prescribers of trimethoprim with polymyxin B.
Adverse effects are very rare. The recommended frequency
of administration is one drop every three hours
(q3 hours) while awake. This is a bit more frequent
than the more common four-times-a-day schedule. As
with most other antibiotic agents, treatment should
continue over seven to ten days.
Trimethoprim sulfate (0.1%) with polymyxin B is
marketed as Polytrim ophthalmic solution by Allergan,
and generically. This is an excellent antibiotic that
enjoys widespread use in treating bacterial conjunctivitis
in children and adults.
Azithromycin
We are all familiar with azithromycin
(Zithromax, Pfizer) by use of the famous
Z-Pak or Tri-Pak. Azithromycin is a
macrolide antibiotic possessing broadspectrum
action against most common
gram-positive pathogens as well as
Chlamydia species. Like all macrolides,
its mechanism of action is inhibition of
protein synthesis.
In eye care, we use azithromycin primarily
to treat chlamydial conjunctivitis, and typically
prescribe it as a single 1,000mg oral dose. In primarycare
medicine, azithromycin is used (and overused) to
treat upper and lower respiratory diseases and sinusitis.
Now, azithromycin is available as a 1% ophthalmic
antibiotic solution under the brand name AzaSite, manufactured
by InSite Vision and licensed to Inspire
Pharmaceuticals, Inc. On the plus side, azithromycin
possesses the ability to achieve high tissue concentrations,
and because of its unique viscous vehicle, DuraSite,
ocular surface residence time is prolonged, which
should further enhance tissue penetration.
This dual characteristic allows for less frequent instilGeneral
Observations and Clinical Pearls
* For bacterial conjunctivitis or prophylaxis, we generally
select an aminoglycoside or a fluoroquinolone. When treating an
infectious keratitis, we use a fourth-generation fluoroquinolone
or fortified antibiotic.
* If we use an aminoglycoside by day and desire an ointment
at bedtime, we would choose either Ciloxan or Polysporin. If we
use a fluoroquinolone by day and desire an ointment at bedtime,
we would choose Polysporin. It is extremely rare to encounter a
condition where both an eyedrop and ointment are needed.
* We have never experienced aminoglycoside corneotoxicity.
Perhaps if dosed frequently for more than one week, and/or the
patient has untreated tear film dysfunction, then such an event
could occur, but that would be very rare. Fluoroquinolones have
considerably less corneotoxic potential than aminoglycosides.
* Whether an aminoglycoside or one of the fluoroquinolones
is selected is not a pivotal decision. The key to effecting a clinical
cure centers on "frequency of administration." As best as can
be anticipated, prescribe a dosing frequency commensurate with
the nature of the disease entity.
­ For moderate to severe bacterial conjunctivitis, dose every two
hours until control is achieved, then consider decreasing to
q.i.d. for four to six more days.
­ For hyperacute bacterial infections, dose hourly along with
Polysporin ointment at bedtime until control is achieved. Once
under control, stop the ointment and reduce eyedrops to q2
hours for four days, then q.i.d. for four days. Consider concurrent
oral Augmentin (amoxicillin/clavulanate potassium,
GlaxoSmithKline) at 875mg b.i.d. for a week if the condition
warrants.
­ For garden variety bacterial conjunctivitis, dose q2 hours for
two days, then q.i.d. for four to five more days.
­ For high probability or firmly diagnosed bacterial keratitis,
dose hourly along with Polysporin ointment at bedtime.
Cycloplege with 5% homatropine or 0.25% scopolamine two
or three times daily. Once the infection shows evidence of
control, stop the ointment and decrease the eye drops to q2
hours for four days, then q.i.d. for four days. If there is any
epithelial toxic SPK, use preservative-free artificial tears p.r.n.
and GenTeal Gel at bedtime.
­ For staphylococcal blepharitis, use bacitracin or Polysporin
ointment at bedtime for two weeks, along with proper
hygiene. If there is secondarily associated eyelid margin
inflammation as evidenced by considerable erythema to the
eyelid margin, then TobraDex ointment at bedtime for two
weeks would be appropriate. TobraDex ointment at bedtime is
also an excellent choice for angular blepharitis, or any expression
of tissue maceration or erosion to the eyelid tissues.
­ For subacute dacryocystitis, Keflex (cephalexin, Dista) 500mg
b.i.d. or Augmentin 875mg b.i.d. p.o. for one week, along with
warm compresses, would be warranted.
REVIEW OF OPTOMETRY JUNE 15, 2007 13A
lations. Dosage is one drop twice
daily (about every eight to 12
hours) for two days, then once daily
for five more days. This regimen
should enhance user-friendliness,
and therefore result in better compliance.
On the negative side,
azithromycin has been very heavily
prescribed for many years, and
therefore has been experiencing
growing resistance.
In the Phase III studies, posttreatment
cultures were negative on
day six in 88.5% of azithromycintreated
eyes vs. 66.4% of vehicletreated
eyes. When success was
defined in more clinically relevant
terms (i.e., discharge and conjunctival
hyperemia), 63.1% of azithromycin-treated
eyes (vs. 49.7% of
placebo-treated eyes) were cured at
day six. As an aside, this is generally
why we often treat bacterial
conjunctivitis with a combination
drug, such as Zylet, TobraDex or
generic Maxitrol--such drugs
address both the infection and the
associated inflammation.
If the patient has an allergy to
erythromycin--the prototypic
macrolide--then avoid use of any
other macrolide, such as azithro-
mycin.
AzaSite 1% ophthalmic solution
comes in a 5ml bottle containing
2.5ml of the medicine. It is preserved
with a low concentration
(0.003%) BAK. It is a Pregnancy B
drug, and is approved for patients
as young as age 1.
So, in the ocean of antibiotics,
there is yet another fish in the sea.
Whether AzaSite performs in a
manner beneficial to our patients,
or fills a special niche, will only
become known after a year or two
of widespread clinical use. At least
initially, we plan to use AzaSite to
treat pediatric bacterial conjunctivitis
and mild to moderate cases of
adult bacterial conjunctivitis.
A final note: Since chlamydial
conjunctivitis is an ophthalmic
expression of systemic disease, this
condition must be treated with the
oral form of azithromycin.
Chloramphenicol
This agent achieves bacteriostasis
by inhibiting protein synthesis. It is
available in both solution (0.5%)
and ointment (1%) form. It is effective
against a broad spectrum of
bacteria, but is not active against
Pseudomonas. Because it is lipidsoluble,
it has excellent penetration
through the cornea.
However, a few cases in the literature
implicate chloramphenicol in
aplastic anemia deaths, and some
believe that even the small, topical
doses in ocular therapy could trigger
bone marrow aplasia in genetically
susceptible individuals.
Because there are many good
alternatives, it might be difficult to
defend a malpractice suit arising
from complications due to this
drug. While it is a very good drug
in a wide variety of ocular infections,
for medico-legal reasons, we
never use it. However, note that
chloramphenicol is the workhorse
ophthalmic antibiotic in Europe
and Australia, being successfully
prescribed over a million times a
year. Chloramphenicol is marketed
by several companies.
Erythromycin
Erythromycin, which is also bacteriostatic,
works by inhibiting protein
synthesis. The topical form is
effective against many gram-positive
and some gram-negative organisms.
However, if used over several
days, staphylococcal resistance may
develop. The drug is only available
as 0.5% ointment. For these reasons,
erythromycin is not a drug of
choice for active therapy.
However, because it is so gentle,
it is an excellent prophylactic antibacterial
when pressure patching
corneal abrasions. Furthermore,
any time there is corneal compromise
from virtually any condition,
where both lubrication and antibacterial
prophylaxis are desired,
erythromycin is an excellent choice.
Erythromycin ophthalmic ointment
is commonly used in labor
and delivery suites for neonatal prophylaxis.
Topical erythromycin was
most commonly known by its original
brand name Ilotycin, by Dista.
Erythromycin ophthalmic ointment
is now generically available from
numerous manufacturers in a 1/8oz.
tube and in a 1g unit-dose tube.
Anti biotics
Is Chloramphenicol OK After All?
In 1982, a landmark article was written by F.T. Fraunfelder linking aplastic anemia deaths
to topical ophthalmic chloramphenicol.1
This effectively killed the chloramphenicol market
in the United States.
This same author revisited the topic in January 2007.2
Newer information revealed that
high-performance liquid chromatography does not detect chloramphenicol in the blood.
This drug is heavily prescribed in Ireland, England, Australia, and the Far East. Indeed, it
is, "one of the most widely prescribed topical antibiotics in the world."2
Regarding a link between aplastic anemia and chloramphenicol, the expert assessment
is "probable;" however, there is no proof of causality. The general guideline: Do not use
chloramphenicol if there is a personal or family history of blood dyscrasia.
In summary, chloramphenicol is, "efficacious, affordable, broad spectrum, and very
rarely causes blood dyscrasias."2
1. Fraunfelder FT, Bagby GC Jr, Kelly DJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.
Am J Ophthalmol 1982 Mar;93(3):356-60.
2. Fraunfelder FW, Fraunfelder FT. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
Am J Ophthalmol 2007 Jan;143(1):145-149. Epub 2006 Nov 13.
REVIEW OF OPTOMETRY JUNE 15, 200714A
While methicillin has not been used clinically for many years, it is
the gold standard for in vitro efficacy in the setting of highly resistant
strains of Staphylococcus aureus, a common ocular pathogen.
A growing concern within the infectious disease community, as
well as the eye-care community, is a bacterial pathogen widely
known as MRSA (methicillin-resistant Staphylococcus aureus).
An article in the November 2006 American Journal of
Ophthalmology, "In Vitro Activity of Fluoroquinolones, Vancomycin,
and Gentamicin Against Methicillin-Resistant Staphylococcus
Aureus Ocular Isolates," provided an updated perspective on this
issue.1
Following are quotes (and/or in-context paraphrases) from
this excellent and timely article:
* "Alarmingly, ocular bacterial isolates are exhibiting increasing
resistance to ophthalmic fluoroquinolones. ... The present study
data demonstrate that ocular surface MRSA isolates have a relatively
high percent of in vitro resistance to the fourth-generation of
fluoroquinolones." These isolates "were nearly universally susceptible
to vancomycin and gentamicin."
* "One of the limitations of many ophthalmic studies that look
at antibiotic efficacy is that standard routine antibiotic susceptibility
values and susceptibility interpretations reported from the clinical
microbiology laboratory are based on the achievable blood
serum concentrations of the antibiotic. These values may not be
directly relevant to topically-applied ophthalmic antibiotic preparations.
It is known that direct application of topical agents to the
eye surface initially provides high concentrations of the agent but
that these levels are generally dissipated rapidly from the tear
film."
* "It is possible that antibiotic resistance determined by standard
in vitro MIC (minimal inhibitory concentration) values could be
overcome when high levels of an available antibiotic are instilled in
topical ophthalmic preparations."
* "Topical fourth-generation fluoroquinolones should not be
regarded as an antibacterial panacea ... as the devastating effects
of rapidly progressive ocular MRSA infection despite treatment
with fourth-generation fluoroquinolones have been described."
First and foremost, in most circumstances the fourth-generation
fluoroquinolones are indeed highly efficacious when properly
administered. The purpose of discussing the topic of resistant
organisms is that such infections, while uncommon, do exist; eye
doctors need to recognize such events and be prepared to prescribe
alternative therapy.
This article appropriately emphasized that laboratory-based in
vitro susceptibility testing has limited in vivo application. To wit, it
clearly has been shown that topical ophthalmic therapy can readily
eliminate bacterial pathogens found to be "resistant" in vitro. The
key to successful antibacterial therapy is frequent (usually hourly)
instillation of the chosen topical antibiotic, since tear and blinking
dynamics rapidly diminish the residence and concentration of the
drug.
If you encounter resistance when using a fluoroquinolone, then
consider (pharmacy-compounded) vancomycin or an aminoglycoside
(commercially available or concentrated via a compounding
pharmacy). This has been shown to be highly successful in the
setting of MRSA resistance. For perspective, systemic MRSA infections
have been shown to be virtually 100% susceptible to systemically-prescribed
trimethoprim with sulfamethoxazole (Septra
and Bactrim are common brand names); we hypothesize that topical
applications of trimethoprim with polymyxin B (Polytrim) could
be another useful medicine ophthalmically. We would recommend
an aminoglycoside as the alternative drug of first choice because
it is readily available, and also "saves" vancomycin for infections
where it is the only effective agent.
The article concludes: "MRSA ocular isolates exhibited a relatively
high rate of in vitro resistance to all fluoroquinolones tested,
including the fourth generation. In contrast, MRSA isolates were
found to be highly sensitive to vancomycin and gentamicin."
Bottom line: First, make an accurate diagnosis. Then choose
your antibiotic of choice and have it instilled at a dosage frequency
deemed appropriate. Last, be prepared to change medicines if you
encounter resistance.
_______________________
Has the use of fourth-generation fluoroquinolones decreased
the rate of post-cataract endophthalmitis? A nice article in the
April 2007 issue of Ophthalmology did not find any change in such
events since the advent of these newer antibiotics. The authors
were unclear as to exactly why this was the case, but felt that,
"The possibility of emerging resistance must be considered."2
They went on to say: "It is disconcerting to see a possible trend
of bacterial resistance to these agents, as was observed with
third-generation fluoroquinolones after their widespread and indiscriminate
use."
1. Kotlus BS, Wymbs RA, Vellozzi EM, Udell IJ. In vitro activity of fluoroquinolones, vancomycin,
and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Am J Ophthalmol 2006 Nov;142(5):72.
2. Moshirfar M, Feiz V, Vitale AT, et al. Endophthalmitis after uncomplicated cataract surgery
with the use of fourth-generation fluoroquinolones: a retrospective observational case
series. Ophthalmology 2007 Apr;114(4):686-91.
New Perspectives on Fluoroquinolones
REVIEW OF OPTOMETRY JUNE 15, 2007 15A
Gentamicin and Tobramycin
Both of these aminoglycosides are broad-spectrum
antibiotics, which are bactericidal by inhibiting protein
synthesis. They are most effective against gram-negative
bacteria, especially Pseudomonas species, but are
also effective against most gram-positive bacteria.
These drugs are available in solution (0.3%)
and ointment (0.3%).
Being aminoglycosides, they can cause
allergic reactions similar to those seen with
neomycin, but are much less likely to do so.
Aminoglycoside toxicity is legendary, but
very uncommon. Clinical signs include
epithelial breakdown (superficial punctate
keratitis, or SPK), injection in the inferior
cul-de-sac, and a weepy erythema and
edema of the eyelid tissues. These responses
are usually not serious and mostly occur
after the drug is used in excess of a week or
two. In our years of clinical practice, we
have never seen such an occurrence at our
hands. For short-term use, these drugs are
excellent, cost-effective choices for treating
bacterial infections.
One of the practical advantages of
these drugs is their generic availability.
This has allowed us to prescribe a highly
effective antibiotic when expense to the
patient was of particular concern.
Fluoroquinolones
Just as prostaglandins reign
supreme in the care of glaucoma,
and steroids reign
supreme in inflammation
control, so do the fluoroquinolones
enjoy nearabsolute
dominance in
managing bacterial
infections, particularly
of the cornea.
There are, for all
practical considerations,
five ocular fluoroquinolone solutions:
* Ciloxan (ciprofloxacin 0.3%, Alcon and generic)
* Ocuflox (ofloxacin 0.3%, Allergan and generic)
* Quixin (levofloxacin 0.5%, Vistakon
Pharmaceuticals)
* Vigamox (moxifloxacin 0.5%, Alcon)
* Zymar (gatifloxacin 0.3%, Allergan)
All of these drugs perform very similarly, with the
two 8-methoxy fluoroquinolones (Vigamox and
Zymar) outperforming the others
against certain gram-positive
organisms. The absolute
key in using any topical
antibiotic is "frequency of
administration" of the eyedrop.
Dosing every few
minutes initially (for
severe infections) or
hourly (for moderate
infections) achieves sufficiently
high minimum
inhibitory concentrations (MIC) to
achieve bacterial control in virtually all
cases. Then once clinical control has been
achieved, decreasing the dosing frequency
for a few more days generally
assures a complete clinical cure. Never
taper an antibiotic below q.i.d. as such
potentially subtherapeutic levels
could foster development of resistance.
The ultimate key in preventing
resistance is simply to avoid using
any antibiotic unless there is a clear
indication to do so.
Since the 8-methoxy fluoroquinolones
are the rage these days, we will
dissect them here:
Both are absolutely excellent drugs, with Vigamox
preferred by a nose; mostly because of proven
enhanced penetration.2,3
There is also an increasing
trend to migrate toward preservative-free products, and
away from BAK when there is an option.
In summary, when faced with a moderate to severe
bacterial eye infection, use Zymar or Vigamox, and use
it aggressively. Lastly, do not lose sight of the fact that
bacterial eye infections in adults are uncommon events.
Know your diagnostic target before you select your
armament! 
1. Solomon R, Donnenfeld ED, Perry HD, et al. Methicillin-resistant Staphylococcus aureus
infectious keratitis following refractive surgery. Am J Ophthalmol 2007 Apr;143(4):629-34.
2. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin
0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology
2005 Mar;112(3):466-9.
3. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin
0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery
patients. Ophthalmology 2005 Nov;112(11):1992-6. Epub 2005 Sep 23.
Anti biotics
Vigamox Zymar
* 0.5% concentration ˇ 0.3% concentration
* pH of 6.8 ˇ pH of 6.0
* Non-preserved ˇ BAK-preserved
* 3ml transparent bottle ˇ 5ml opaque bottle
REVIEW OF OPTOMETRY JUNE 15, 200716A
T
he ability of steroids to suppress
inflammation (clinical
efficacy) is based on two
factors: potency (as compared on a
mg-per-mg basis) and bioavailability
(the ability to penetrate into target
tissues).
The most clinically effective of
the ophthalmic corticosteroids are
loteprednol and prednisolone. As
such, they enjoy the most widespread
use.
Loteprednol
Almost all of the traditional generation
corticosteroids are ketonebased
formulations. Loteprednol
ushered in an entirely new generation
of corticosteroids using an
ester base. The keystone to this new
formulation is that the human body
possesses abundant esterases, but
has no ketones. Ketone-based
steroids such as prednisolone and
dexamethasone linger in tissues,
which renders good therapeusis but
concurrently places patients at risk
for undesirable side effects such as
posterior subcapsular cataracts and
increased IOP. In contrast, esterbased
steroids provide a potent
anti-inflammatory effect, then enzymatic
degradation of the steroid
occurs, minimizing the potential for
development of adverse side effects.
With all steroids, the key to a
clinical cure is frequency of instillation.
It is difficult to give specific
clinical guidance in written text
because the frequency of instillation
(and indeed, the steroid prescribed)
may vary considerably depending
on the nature and severity of the
clinical condition. That said, we
usually treat most significant
inflammatory conditions
with Lotemax (loteprednol
0.5%, Bausch &
Lomb) every hour or
two for a few days
until the condition
comes well under
control. We then
taper down to q.i.d.
for a few days, then
b.i.d. for a few days,
then stop.
Since Pred Forte is
slightly more efficacious than
loteprednol, we use Pred Forte to
The epidemiology of eye disorders is largely one of inflammation. For this reason,
this class of drugs is the most important to master.
CORTICOSTEROIDSCORTICOSTEROIDS
Topical Corticosteroid Drugs
BRAND NAME GENERIC NAME MANUFACTURER PREPARATION BOTTLE/TUBE
Maximum Strength Steroids
Inflamase Forte, prednisolone sodium Novartis solution 5ml, 10ml, 15ml
and generic phosphate 1%
Lotemax loteprednol etabonate 0.5% Bausch & Lomb suspension 2.5ml, 5ml, 10ml, 15ml
Pred Forte, and generic prednisolone acetate 1% Allergan, and generic suspension 1ml, 5ml, 10ml, 15ml
Vexol rimexolone 1% Alcon suspension 5ml, 10ml
Moderate Strength Steroids
eFlone fluorometholone acetate 0.1% Novartis suspension 5ml, 10ml
Flarex fluorometholone acetate 0.1% Alcon suspension 2.5ml, 5ml, 10ml
FML, and generic fluorometholone alcohol 0.1% Allergan suspension 1ml, 5ml, 10ml, 15ml
FML S.O.P. fluorometholone alcohol 0.1% Allergan ointment 3.5g
Pred Mild, and generic prednisolone acetate 0.12% Allergan suspension 5ml, 10ml
REVIEW OF OPTOMETRY JUNE 15, 2007 17A
treat most cases of uveitis and
severe episcleritis. Otherwise, we
use Lotemax for the remaining host
of ocular inflammatory conditions.
Loteprednol is formulated as an
ophthalmic suspension. It is available
in two concentrations: 0.5% as
Lotemax and 0.2% as Alrex.
Alrex is approved for treating
allergic conjunctivitis, and works
well for this condition. For most
cases of ocular allergy, we initiate
therapy with an antihistamine/mast
cell stabilizer, such as Patanol. But if
there is any evident inflammation
(such as conjunctival injection or
chemosis), we would unhesitatingly
prescribe Alrex (or even Lotemax).
Prednisolone
Studies show that prednisolone
has the greatest anti-inflammatory
efficacy of all topical ophthalmic
steroids, and that prednisolone
acetate 1% as Pred Forte (Allergan)
is the most effective of the topical
ophthalmic steroids for the treatment
of uveitic and corneal inflam-
mations.1
It is well suited for
treating severe forms of ocular
inflammation such as episcleritis,
iritis, chemical/thermal burns of the
cornea, and other severe ocular
inflammatory conditions. Prednisolone
in suspension form
is the most effective drug
for treating iridocyclitis,
due to its ability to penetrate
the cornea.
As with any steroid,
prescribe frequent
instillation schedules
until the inflammation
is under control, then
begin to taper the therapy
based upon the nature of--and
the response of--the individual con-
dition.
Prednisolone eye drops are available
in 1% and 1/8% concentrations,
of which the 1% is by far the
more clinically useful. No ointment
form is available.
Be sure to instruct your patients
to shake any suspension formulation
prior to each instillation. This
instruction should be given verbally
as well as indicated on your prescription.
Some pharmacists will
occasionally dispense a generic
product, even if you have signed
above "Dispense as Written."
Remember that when absolute
maximum effect is required, nothing
surpasses Pred Forte.
Dexamethasone
In its approved concentration,
dexamethasone is less clinically
effective than prednisolone and has
a greater propensity to raise
intraocular pressure, making it a
drug of second choice.
It is available in suspension
(0.1%) and solution (0.1%). Maxidex
(Alcon) is the common suspension
form of dexamethasone.
Decadron (Merck) is the common
solution. These eyedrops are rarely
used in clinical care because of suboptimum
efficacy and the potential
for undesired side effects.
Fluorometholones
Fluorometholones are a unique
class of corticosteroid formulations.
They possess good to excellent antiinflammatory
properties, while having
a diminished propensity to
cause secondary IOP increase.
To understand why iťs necessary to taper steroids, rather than
halt them abruptly, we must first understand the body's system for
regulating natural steroids in the bloodstream.
The hypothalamus produces a substance called corticotropic
releasing factor, or CRF.
This substance travels to the anterior pituitary and triggers the
release of adrenocortotropic hormone, or ACTH. This substance
causes the adrenal cortex to up-regulate the production of hydrocortisone
and corticosterone, the naturally occurring steroids.
When the level of the natural steroids in plasma increases, the
production of ACTH declines. This negative feedback system helps
maintain homeostasis of hydrocortisone and corticosterone.
When a patient takes synthetic steroids over a long period of
time, the adrenal cortex slows its production of physiologic
steroids. This can result in atrophy of the adrenal cortex and even
suppression of pituitary function. This is one reason why steroids
must be gradually tapered--it gives the adrenal cortex time to
start producing the normal level of natural steroids again. To
abruptly stop synthetic steroids could potentially leave the body
with abnormally low levels of steroids.
Though this phenomenon is more pronounced with systemic
steroids, it can occur with topically administered ophthalmic
steroids, as well. One study demonstrated that 0.1% dexamethasone
sodium phosphate ophthalmic solution, one drop four times a
day for six weeks, resulted in a decreased level of the natural
steroids.1
Of course, only rarely would such a protracted dosing
schedule be prescribed.
A more important reason for tapering ophthalmic steroids is the
rebound effect of local inflammation. Remember that steroids suppress,
but do not resolve, the underlying inflammation. Abruptly
discontinuing topical steroids may allow the suppressed inflammation
to bounce back. A good rule of thumb: taper dosage frequency
by about a 50% reduction once inflammation control is
achieved. One example: q1h for two days; q2h for two days; q.i.d.
for four days; b.i.d. for four days. Or, q.i.d. for one week, then b.i.d.
for four more days.
1. Krupin T, Mandell AI, Podos SM, Becker B. Topical corticosteroid therapy and pituitaryadrenal
function. Arch Ophthalmol 1976 Jun;94(6):919-20.
Corticosteroids
Why Taper Steroids?
REVIEW OF OPTOMETRY JUNE 15, 200718A
There are two formulations of fluorometholone,
the alcohol and the
acetate. Both are useful in some primary
inflammatory conditions.
* Fluorometholone alcohol. This
product is a good, moderatestrength
ophthalmic suspension. It
is used very commonly to treat a
host of mild to moderate
ocular surface inflammatory
conditions. It is also
a rational choice in
treating chronic inflammations
requiring
long-term (beyond
three to four week)
therapy such as lowgrade
chronic iridocyclitis,
and some cases
of ocular allergy. Its
usefulness in chronic care lies in its
reduced tendency to cause secondary
IOP increase. Although chronic
use of any steroid can result in
increased IOP, the fluorometholone
class of steroids is less likely to do
so than traditional ketone-based
products.
Fluorometholone alcohol is available
in both 0.1% and 0.25% susThe
two most common eyelid inflammatory
conditions are anterior blepharitis and
eczematoid contact blepharodermatitis.
Regarding blepharitis, the cutaneous tissues
of the external aspect of the eyelid
may or may not be inflamed; that is determined
by clinical observation--are the
tissues the normal skin coloration, or is
there obvious redness to these tissues?
The more important question is, what is
the best way to restore these tissues to
normal?
STAPHYLOCOCCAL BLEPHARITIS
Staphylococcal species can produce
exotoxins that cause tissue inflammatory
responses, while seborrheic blepharitis
generally does not evoke significant cutaneous
response. The staph exotoxins can
produce general cutaneous erythema
(and, to a lesser extent, edema). In
advanced cases, the exotoxins can also
lead to ulcerative blepharitis.
The two-pronged approach to treating
staphylococcal blepharitis is to use a
combination antibiotic/steroid ointment,
such as TobraDex (tobramycin/dexamethasone,
Alcon). This therapeutic
approach accomplishes two goals: it minimizes
resident staph populations; and it
simultaneously suppresses the associated
tissue inflammation. When expense is a
concern, a generic equivalent of Maxitrol
(neomycin/polymixin B/dexamethasone,
Alcon) ophthalmic ointment can be pre-
scribed.
Have patients with problematic staph
blepharitis rub the prescribed ointment in
the eyelid margins twice daily for two to
five days, then just at bedtime for one to
three more weeks. For cosmetic concerns,
recommend a light application in the
mornings, and then a more liberal application
at bedtime. Carefully educate patients
as to the target tissues, and use your finger
or a cotton swab to show exactly
where the eyelid margin is. Provide this
demonstration in addition to verbal direction:
"right along the base of the eyelashes
where they come out of the eyelid."
Lid scrubs can, and should, be a major
component to the control of both staphylococcal
and seborrheic blepharitis. Some
doctors employ these scrubs initially; others
get the tissues under control medically,
then introduce lid scrubs as a hygienic
maneuver to maintain the health of the
eyelid tissues long-term. We have been
impressed with eyelid cleaners, such as
SteriLid (Advanced Vision Research), and
have now largely abandoned use of baby
shampoos. We have heard of many misadventures
with baby shampoos, and are
glad to have these newer, blepharitis-specific
eyelid hygiene products available for
our patients.
CONTACT BLEPHARODERMATITIS
Now leťs turn our attention to the itchy
and/or irritated eyelid. With very rare
Relative Clinical Efficacy of
Steroids
Here, based on our clinical experience
and the comparative information we
have available, we grade the relative
efficacy of the topical steroids:
Hydrocortisone 1% . . . . . . . . . . . . . 1
Prednisolone 1/8% . . . . . . . . . . . . . 2
Medrysone 1% . . . . . . . . . . . . . . . . 2
Loteprednol 0.2% . . . . . . . . . . . . . . 2.5
Fluorometholone alcohol 0.1% . . . . 3
Dexamethasone 0.1% . . . . . . . . . . . 4
Fluorometholone acetate 0.1% . . . . 4
Rimexolone 1% . . . . . . . . . . . . . . . . 4.5
Loteprednol 0.5% . . . . . . . . . . . . . . 4.5
Prednisolone 1% . . . . . . . . . . . . . . . 5
Anti-inflammatory Therapy for the Eyelids
Most cases of staphylococcal blepharitis
result in significant eyelid inflammation,
which can be treated with an
antibiotic/steroid combination.
Tissue inflammation, as evidenced by
`angular blepharitis,' can be healed
with an antibiotic/steroid combination.
Corticosteroids
exception, these patients are women.
Contact blepharodermatitis, or eczematoid
blepharodermatitis, is most commonly a
delayed, type 4 hypersensitivity reaction to
some substance. The most common
offender seems to be the formaldehyde
breakdown products of eyelid cosmetics,
particularly fingernail polish. Contact blepharodermatitis
is also seen with
neomycin, poison oak/ivy, and various
other, often idiopathic, sensitizing agents.
There can be tissue erosion as evidenced
by lateral canthal maceration and
irritation. All these eyelid afflictions are the
result of tissue inflammation, and naturally
respond to topical corticosteroid suppression.
There are numerous such corticosteroid
medications available. We choose to
keep our clinical toolbox simple, so we
have two workhorses for these conditions:
* FML (fluorometholone, Allergan)
ophthalmic ointment. This is the only
standalone ophthalmic corticosteroid available.
FML works well clinically, but has
three limiting factors: it is expensive; it
comes only in a 1/8oz. tube; and is available
only as an ointment (as opposed to a
lotion or cream). The 1/8oz. size is generally
sufficient to treat most cases of eyelid
dermatitis, however.
* Triamcinolone cream. Our favorite
by far is the "non-ophthalmic" drug, triamcinolone.
This is a low- to moderatepotency
corticosteroid that has three
advantages: it is inexpensive as a generic;
it comes in a large, 4oz. tube; and is available
as an ointment, lotion, and cream. It
is available in three concentrations--
0.025%, 0.1%, and 0.5%. We chose to
prescribe the 0.1% concentration early on
and have stayed with it because of its
excellent clinical performance. Our female
colleagues advised us to use a cream
vehicle, so we always prescribe triamcinolone
0.1% cream when anti-inflammatory
therapy is indicated.
Whether to prescribe FML ophthalmic
ointment or 0.1% triamcinolone cream is a
very practical decision. If the patient is
new, or in any way appears potentially
particular, hard to please, questioning, or
apprehensive, we prescribe FML. If, on the
other hand, the patient is well known to
the practice, has a trusting relationship
with us, and is rational and reasonable,
then we prescribe triamcinolone cream.
As a non-ophthalmic formulation, the
triamcinolone tube has, in standard-sized
font, a statement saying: "not for ophthalmic
use." We have even had pharmacists
tell patients, "You're not supposed to
use this near your eyes." To quell any
uncertainty about this on the patienťs
part, we are always proactive in telling our
patients for whom we prescribe triamcinolone
about this statement, and reassure
them we have successfully used the medication
with hundreds of our patients over
the years. We have never had any problem
in any way whatsoever with this approach.
It is a sound, rational, well-proven, costeffective
treatment for achieving tissue
restoration in patients with clinically significant
inflammatory conditions of the eyelid
skin.
You may ask, "But what about thinning
of the eyelid skin with steroid use?"
Steroid preparations certainly have the
potential to cause thinning, but in our 50plus
combined years of clinical practice,
we have never seen this occur with 0.1%
triamcinolone cream. Two main reasons
for skin thinning are: use of "high-potency"
formulations (which this is not), and/or
prolonged or repeated use. We never prescribe
high-potency corticosteroids (such
as betamethasone), and we advise the
patient not to continue use of the medication
for longer than the prescribed time.
Although triamcinolone comes in a 4oz.
tube, we carefully inform our patients to
use the medicine "as directed," i.e., two or
three times a day for three to four days,
then just at bedtime for four to six more
days.
To repeat: We have had excellent success
using this approach, and are excited
that such an easy, simple, cost-effective
medicine is available. While OTC hydrocortisone
may work well for very mild cases
of blepharodermatitis, for the cases we
see in our offices, we always prescribe
FML or triamcinolone 0.1% cream.
What about steroid-sparing therapy
such as Protopic (tacrolimus, Astellas
Pharma) or Elidel (pimecrolimus, Novartis)?
These agents are broadly macrolide
immunosuppressants. They work by
inhibiting T-lymphocyte activation. These
drugs are approved as "second-line" therapy
for mild to moderate atopic dermatitis.
Via expert opinion we have obtained from
our colleagues in the dermatologic community,
these preparations do not perform
as effectively as corticosteroid preparations.
But, they are occasionally used
when long-term dermatitis suppression is
indicated. Bottom line, we see little or no
reason to prescribe these agents in light of
the excellent success we have had with
time-honored, traditional approaches as
we have just described.
In summary, the care of patients with
anterior blepharitis and contact/eczematoid
blepharodermatitis is straightforward,
and is easily treated with conventional
medical approaches. In the case of blepharodermatitis,
should the patient exhibit
multiple recurrences, consider a consult
with an allergist or dermatologist.
Regarding posterior blepharitis (meibomitis),
warm soaks followed by eyelid
massage are good initial approaches. A
three- to nine-month course of oral doxycycline
(or minocycline) may be needed to
achieve success if initial methods fail. We
generally prescribe a 50mg tablet once
daily, and monitor the patient every three
months until clinical control is achieved.
REVIEW OF OPTOMETRY JUNE 15, 2007 19A
Contact blepharodermatitis can be
easily treated with topically-applied
corticosteroid formulations, such as
triamcinolone or fluorometholone.
pensions, and 0.1% ointment. The
0.25% suspension offers little, if
any, clinical advantage over the
0.1%, and is rarely used. These are
marketed under the brand name
FML (Allergan), and are
also available generically.
* Fluorometholone
acetate. This is the
more clinically active
form of the more familiar
FML. Fluorometholone
acetate is
marketed as Flarex
ophthalmic suspension
(Alcon), and
Eflone ophthalmic suspension
(Novartis Ophthalmics),
and is available generically.
The acetate formulation
confers upon
fluorometholone
greater clinical efficacy
(which may or
may not be needed for
each individual case),
while still enjoying the
relative IOP-sparing
effect of the fluorometholones. Its
clinical effectiveness is about midway
between FML and 1% prednisolone
acetate.
The indications for this product
are essentially the same as for the
other corticosteroids. It is generally
wise to adhere to recognized "community
standards of care" in drug
selection. Keep this medico-legal
principle in mind when using any
drug.
Rimexolone
Rimexolone is a
potent, relatively safe
preparation and is
close to--but not as
efficacious as--1%
prednisolone acetate;
yet its decreased
propensity to raise
intraocular pressure
is very similar to that
of the fluorometholones.
It is marketed as
Vexol 1% ophthalmic suspension
(Alcon).
The uniqueness of Vexol is that it
is the first steroid to be approved by
the FDA for postoperative inflammation
control. (Pred Forte is the
gold standard for this purpose, yet
has no FDA indication for such a
use.) Rimexolone is also approved
for the treatment of anterior uveitis.
In summary, corticosteroids are
the mainstay of medical therapeutics
in office-based eye care. At least
80% of the prescriptions we write
within the context of acute eye care
are for a steroid or combination
antibiotic-steroid medicine. It is not
that we have a particular love for
steroids, but we greatly enjoy seeing
our patients with acute red eye
recover quickly.
Nothing achieves this goal better
than a corticosteroid medication
when the condition is inflammatory
in nature. 
1. Leibowitz HM, Kupferman A. Antiinflammatory
Medications. In: Holly FJ, ed. Clinical Pharmacology of the
Anterior Segment. Int Ophthalmol Clinics 1980;20(3):117-
134.
REVIEW OF OPTOMETRY JUNE 15, 200720A
Corticosteroids
The Very Few Steroid Contraindications
* Herpes simplex infectious epithelial keratitis. However, steroids are often indicated
when managing stromal immune forms of herpetic keratitis.
* Acute bacterial infections. The only exception: when treating bacterial infections and
there is much associated inflammation. In this case, a good combination antibiotic/steroid
such as Zylet or TobraDex is often a wise choice.
* Significant epithelial compromise. Again, the only exceptions are cases in which the
breach of epithelial integrity is the result of inflammation. Here, a good combination
antibiotic/steroid may be needed to potentiate re-epithelialization.
Steroid Indications
Below are examples of when
steroids may be indicated:
* Iritis, iridocyclitis
* Episcleritis
* Chemical trauma
* Corneal infiltrates
* Angular blepharitis
* Peripheral corneal erosions
* U.V. keratitis
* Phlyctenulosis
* Contact blepharodermatitis
* Glaucomatocyclitic crisis
* Vernal keratoconjunctivitis
* Thygeson's superficial punctate keratitis
* Stromal keratitis
* Epidemic keratoconjunctivitis
* Uveitic glaucoma
* Ocular trauma
* Staphylococcal exotoxin blepharoinflammation
* Postoperative care
* Eczemoid blepharitis
* Corneal microcystic edema
... and a host of other nonspecific ocular inflammatory conditions.
Keratic precipitates as seen in anterior uveitis.Keratic precipitates as seen in anterior uveitis.
Visit our website: www.eyeupdate.com
Past recipients of the "Glaucoma Educator of the Year" Award by the
American Academy of Optometry
Authors of Review of Optometry's annual Clinical Guide to Ophthalmic Drugs
by Drs. Ron Melton and Randall Thomas
"CURRENT THERAPY IN OCULAR DISEASE"
This lecture is 20 hours of COPE-approved continuing education, filled with clinically
relevant, "take to the office" pearls. This sought-after post-graduate education symposium
is expertly taught all over North America by Drs. Ron Melton and Randall Thomas.
Join your colleagues for professional enrichment at its best.
* Friday, November 2 - Sunday, November 4, 2007
Hilton Suites Hotel and Conference Centre
Markham, Ontario, Canada
Join your fellow optometrists in Ontario, who only recently obtained prescriptive authority,
for what is sure to be a stimulating course, less than a half hour from downtown Toronto.
Contact: Dr. Paul Chris or Ms. Georgina Tappenden
Vision Institute of Canada, 16 York Mills Road, Suite 110, Toronto, Ontario M2P 2E5
(416) 224-2273
e-mail: visioninstitute@globalserve.net
www.visioninstitute.optometry.net
* Thursday, June 19 - Sunday, June 22, 2008
The Holiday Inn Georgetown
Washington, D.C.
Join your colleagues in our nation's capital for this nationally-acclaimed symposium
located in the hub of all D.C. attractions.
Contact: Dr. Antoinette D. Parvis
EYE-SIGHT 20/20, 216 Main Street, Oxford MA 01540
(508) 987-9679
e-mail: drparvis2020@hotmail.com
www.eyesightce.com
Comments from previous attendees:
"Excellent, practical, informative lectures, delivered with efficiency and humor. Good handouts."
"The speakers delivered excellent, relevant information in an entertaining manner."
"This 20-hour course was the best I've ever attended."
"Very practical, useful, take-it-back-to-the-office material. Love it."
"This course is the best course available anywhere for the practice of optometrists. Almost every
word spoken is meaningful and significant."
Current Therapy in
Ocular Disease
Current Therapy in
Ocular Disease
CLINICAL CASES FOR
COMBINATION DRUGS
CLINICAL CASES FOR
COMBINATION DRUGS
REVIEW OF OPTOMETRY JUNE 15, 200722A
T
his class of ophthalmic
drugs is highly useful and
rivals the pure topical corticosteroids
in the treatment of the
acute red eye. As with most drugs,
there are clear indications and clear
contraindications, with a gray zone
in between.
In order to prescribe a combination
drug with clinical precision,
one has to have a masterful understanding
of both antibiotics and
corticosteroids. As many as half of
all red eyes that we see are treated
with a combination drug, rather
than either a steroid or antibiotic
alone. This observation clearly
acknowledges two clinical realities:
* The need for topical antibiotics
alone is relatively low, and
* Almost all acute red eyes have a
significant inflammatory compo-
nent.
So, how does the astute clinician
choose between a pure steroid and
a combination drug? The answer is
relatively straightforward, but, as
always, there are exceptions to generalizations.
The pivotal issue is the
integrity of the corneal epithelium.
If the corneal epithelium is intact,
there is little or no reason for prophylaxis
against opportunistic bacterial
pathogens. This is because an
intact epithelium is itself a firewall
of defense. If there is significant
epithelial compromise, then a combination
drug may perfectly match
the clinical need.
Perhaps half of all inflamed eyes require a combination drug, rather than an
antibiotic or steroid alone.
Corticosteroid/Antibiotic Combination Drugs
BRAND NAME MANUFACTURER STEROID ANTIBIOTIC PREPARATION BOTTLE/TUBE
Blephamide Allergan prednisolone sodium sulfacetamide 10% susp./ung. 2.5ml, 5ml, 10ml/3.5g
acetate 0.2%
Cortisporin Monarch hydrocortisone 1% neomycin 0.35%, suspension 7.5ml
polymyxin B 10,000u/ml
Dexacidin Novartis dexamethasone 0.1% neomycin 0.35%, suspension 5ml
polymyxin B 10,000u/ml
FML-S Allergan fluorometholone 0.1% sodium sulfacetamide 10% suspension 5ml, 10ml
Isopto-Cetapred Alcon prednisolone sodium sulfacetamide 10% susp./ung. 5ml, 15ml/3.5g
acetate 0.25%
Maxitrol Alcon dexamethasone 0.1% neomycin 0.35%, susp./ung. 5ml/3.5g
polymyxin B 10,000u/ml
NeoDecadron Merck dexamethasone 0.1% neomycin 0.35% solution 5ml
Poly-Pred Allergan prednisolone acetate 1% neomycin 0.35%, suspension 5ml, 10ml
polymyxin B 10,000u/ml
Pred-G Allergan prednisolone acetate 1% gentamicin 0.3% susp./ung. 2.5ml, 10ml/3.5g
TobraDex Alcon dexamethasone 0.1% tobramycin 0.3% susp./ung. 2.5ml, 5 ml/3.5g
Vasocidin Novartis prednisolone sodium sodium sulfacetamide 10% solution 5ml, 10ml
phosphate 0.25%
Zylet Bausch & Lomb loteprednol 0.5% tobramycin 0.3% suspension 2.5ml, 5ml, 10ml
REVIEW OF OPTOMETRY JUNE 15, 2007 23A
Remember that the conjunctiva
will be inflamed in any patient presenting
with an acute red eye.
Simply put, the eye is red because it
is inflamed. Also, the conjunctiva
will be inflamed in almost all cases
in which keratitis is present. With
either keratitis (with an intact
epithelium) or non-infectious conjunctivitis,
we almost always use a
topical steroid.
If the accurate diagnosis of bacterial
conjunctivitis is made, the decision
is whether to prescribe an
antibiotic or a combination drug.
The prime determinants are
twofold:
1) the severity of the infection,
and
2) the degree of conjunctival
injection.
If the infection presents with
marked mucopurulence, we would
likely treat with a pure antibiotic,
such as moxifloxacin (and perhaps
even culture if the infection was
severe). If the infectious expression
was only mild to moderate, the
degree of conjunctival injection
would be the overriding issue in
choosing between an antibiotic and
a combination drug such as Zylet
(loteprednol/tobramycin, Bausch &
Lomb), TobraDex (dexamethasone/
tobramycin, Alcon), or Maxitrol
(dexamethasone/neomycin/polymyxin
B, Alcon). We stress again
that bacterial infection is uncommon,
especially relative to the
numerous expressions of noninfectious
conjunctivitis.
An exception is the patient
who presents with what appears
to be a low grade bacterial conjunctivitis
(i.e., minimal discharge),
yet with moderate to
marked conjunctival injection.
The patient usually complains
that the affected eye was "stuck
together when I woke up."
Commonly, by the time the patient
arrives at your office, any excess
debris may have been cleaned
from the lids and lashes.
Further, blinking has moved
considerable mucopurulent
debris down the nasolacrimal
system so that the
objective slit lamp findings
reveal only minimal
microparticulant debris in
the lacrimal lake; a clear,
non-staining cornea; and/or a
red eye. Here is where a combination
product is used mainly to
address the conjunctival inflammation,
while concurrently eliminating
any infectious component, even
when the cornea is uninvolved.
When there is significant corneal
epithelial compromise, we almost
always use a combination drug. For
most cases, the choice of
drug class is that simple.
The first blockbuster,
highly effective combination
antibiotic/corticosteroid
was Maxitrol,
containing neomycin,
polymyxin B and dexamethasone.
Maxitrol
became a real workhorse
in primary eye
care. However, the
occasional neomycin reaction, while
not a major issue, prompted investigation
into a "new and improved"
combination drug.
Thus was born TobraDex,
which replaced the neomycin
and polymyxin B with
tobramycin. This drug, like
Maxitrol, enjoyed market
dominance, though from
time to time, and again not
a major issue, intraocular
pressure increases
prompted an investigation
into a "new and improved"
combination drug.
Thus was born Zylet. Keeping
the highly efficacious tobramycin,
the dexamethasone was replaced
with a newer generation, esterbased
corticosteroid, loteprednol.
Now with Zylet, we have
excellent antibiosis along with
the safety and potency of loteprednol.
It is available in
2.5ml, 5ml and 10ml bottles.
Now that we have 90% of
this topic covered, we need to
spend the bulk of this article
discussing other various exceptions
and modifications to this
rather simple decision tree. The best
way to teach the concepts for drug
class choice is perhaps by looking at
a few specific clinical entities:
Thygeson's Superficial Punctate
Keratopathy (SPK). This not-souncommon
keratitis is seen in
young to middle-aged patients. The
classic symptoms are foreign body
sensation, photophobia and
lacrimation. This idiopathic condition
has cycles of exacerbation and
remissions over the course of 10 to
20 years, until it finally abates. It is
during these exacerbations when
symptoms prompt the patient to
seek medical attention. This usually
Combination Drugs
A classic presentation of the corneal
staining pattern of Thygeson's SPK. (The
fellow eye was nearly identical.) This is
one of the unusual cases of keratitis in
which a modestly-potent corticosteroid,
such as Alrex (q.i.d. for one week; b.i.d.
for one to two more weeks), quickly
brings resolution in most cases.
REVIEW OF OPTOMETRY JUNE 15, 200724A
bilateral keratitis shows several
tiny, usually central, subtle (but
readily seen) staining defects with
fluorescein dye. (Note that about
20% of cases are unilateral, so differentiating
Thygeson's from herpes
simplex must be done; here is
where corneal sensitivity testing can
be useful. Also, the Thygeson's eye
will generally be white, or minimally
injected, whereas the herpetic
eye will generally be considerably
injected.)
If the patient is significantly
symptomatic, a topical corticosteroid
readily suppresses the keratitis
and its attendant symptoms. If
the presenting symptoms are tolerable,
then artificial tears and patient
education are likely all that is
needed. However, the teaching
point here is that even though there
is some punctate staining in acute
Thygeson's SPK, all that is needed
is a topical steroid. This is the uniform
recommendation in authoritative
textbooks.
While 1% concentrations of topical
steroids are indicated in most
inflammatory eye conditions,
Thygeson's is steroid sensitive.
Therefore, our drug of choice in
these cases is Alrex (loteprednol
0.2%, Bausch & Lomb). We generally
treat symptomatic patients
q.i.d. for one week, then b.i.d. for
one to four weeks, until the phase
of exacerbation subsides. Artificial
tears complement virtually all acute
ocular surface conditions, but there
is no need for an antibiotic.
Epidemic Keratoconjunctivitis
(EKC). If the EKC is severe, and
especially if tarsal conjunctival
membranes have formed, there can
be epithelial compromise. The key
here is to physically peel away these
membranes, as they exert toxic and
mechanical trauma to the epithelium.
Be sure to wear gloves when
performing this procedure, as
minor bleeding often results.
These membranes are a marker
of intense inflammation, and as
such, corticosteroid therapy is of
paramount importance. We generally
use Lotemax (loteprednol
0.5%, Bausch & Lomb) q.i.d. for a
week. By the end of this period,
natural healing will likely have
occurred and the steroid can be
stopped, or tapered to b.i.d. for a
few more days. While a combination
drug, such as Zylet, TobraDex
or generic Maxitrol, could be used
here, we almost always use a pure
topical steroid. Aminoglycoside
toxicity on an already toxic ocular
surface is probably not a practical
concern, but could be in instances
in which the patient has concurrent
dry eye.
In many advanced cases of
EKC, subepithelial infiltrates
(which do not stain) can
develop. When these cause
symptomatic, visual compromise,
a steroid will readily
clear this unique, immune
keratitis. This generally
requires two to four months
of tapering therapy. Our routine
has been to use Lotemax
q.i.d. for one month, t.i.d.
for one month, b.i.d. for one
month, and then once-daily
for one month. It usually
takes two to four months for
sufficient viral antigen to be
physiologically leeched from
stromal residence. So when
the steroid taper is completed, any
small infiltrates that might reform
should be symptomatically minimal,
or silent.
Of note, antibiotics and combination
drugs have little or no role
in treating patients with adenoviral
infections because concurrent bacterial
infection is exceedingly rare.
For several years now, we have
successfully treated symptomatic
patients with acute, grade II or
higher EKC with a 60-second treatment
of 5% Betadine Sterile Ophthalmic
Prep Solution (povidone/
iodine, Alcon) followed by ocular
surface lavage. This accomplishes
two objectives. First, eradication of
the bulk of the adenoviral load hasDevelopment
of thick membranes can be seen in
more advanced cases of EKC. After instillation of
topical anesthetic, these membranes (note both
superior and inferior tarsal) were peeled away
with minimal bleeding. Zylet was then used q2h
for two days, then q.i.d. for four days.
Pearls for Using Combination Drugs
* Anytime you see any process at or near the limbus, it is inflammatory in nature.
Herpetic infection can present at this area, but will typically be linear (as opposed to oval)
in morphology.
* In any acute, unilateral red eye with a serous discharge, be sure to rule out herpetic
keratitis.
* Never (or rarely) taper combination drugs below q.i.d. because subtherapeutic levels of
antibiotic set the stage for antibiotic resistance.
* In the context of a red eye with a mild secondary iritis, instill a short-acting cycloplegic
agent, particularly if a pure antibiotic is used. A combination product will generally eliminate
such an iritis without the need for a cycloplegic, though this is a fine clinical point.
REVIEW OF OPTOMETRY JUNE 15, 2007 25A
tens acute symptomatic recovery.
Second, since the virus particles residence
time has been considerably
truncated, the potential for viral
antigenic (stromal immune) keratitis
is largely pre-empted.
Note: since Betadine stings,
always pre-treat the cornea with a
drop of proparacaine. Furthermore,
to diminish any patient discomfort,
we generally instill a drop or two of
Voltaren (diclofenac sodium,
Novartis Ophthalmics) or Acular
LS (ketorolac tromethamine,
Allergan) before, and again after
the treatment.
Following the in-office treatment
as described above, we always prescribe
Lotemax, usually q.i.d. for
four to six days, to dampen or eliminate
any residual inflammatory
keratoconjunctivitis.
Herpes Simplex Keratitis (HSK).
Here is another condition that commonly
demonstrates considerable
epithelial compromise.
Since corticosteroids cause local
immunosuppression, their use is
contraindicated--an exceedingly
Combination Drugs
Confusion abounds in eye care regarding the diagnosis and treatment
of contact lens-related keratitis, although in most cases,
these clinical presentations are rather straightforward. Of course,
our greatest concern is vision loss from a central bacterial
corneal ulcer. The good news is that such ulcers are exceedingly
rare. The problem, however, is threefold: 1) corneal infiltrates are
quite common occurrences; 2) there is a lot of uncertainty among
eye doctors as to the differentiation of corneal lesions; and 3) the
ever-looming concern, "Is this the beginning of a potentially
vision-threatening ulcerative process?" This last point is particularly
worrisome when a positive epithelial defect is present.
Corneal hypoxia is the most common cause of corneal infiltrative
events, but with the advent of the super oxygen-permeable
silicone hydrogel lenses, we hope to see a dramatic decrease in
the hypoxic-related keratitis.
Hypoxia can result in a cascade of events that result in leukocytic
chemotaxis into the anterior stromal tissues. Once ample
leukocytic recruitment occurs, exocytotoxic chemicals can lead to
retrograde demise of some of the overlying epithelium as evidenced
by a positive fluorescein staining defect. It is these circumstances
that lead many doctors to erroneously assume the
worst and start the patient on a course of topical antibiotics.
While this does no harm, it does no more good than simply discontinuing
the use of the contact lenses, which, of course, is the
first step of treatment for all contact lens-related eye problems. A
steroid, in combination with an antibiotic, is perfectly suited to
suppress the immune/inflammatory response, while protecting
the cornea against any opportunistic bacterial infections.
There are numerous parameters to evaluating the differential
diagnosis of leukocytic infiltration (largely from hypoxia) versus
stromal opacification lesions (largely from bacterial infection).
(See "Infectious Ulcers vs. Sterile Infiltrates," on page 28A.)
Leťs look at some risk factors for ulcerative keratitis so that
we can better quantify the likelihood of such occurrences:
* Poor tear film function
* Uncontrolled staphylococcal blepharitis
* Smoking
* Swimming while wearing contacts (esp. in fresh water)
* Being under age 22 
While this is not an exhaustive list, it gives us some red flags
by which we can exercise our clinical judgment, and enhance our
patient education.
If you truly feel your patient has an infectious lesion, then start
them on a fluoroquinolone such as Vigamox or Zymar every 15
minutes for three to six hours, then hourly until bedtime. We have
our patients instill generic Polysporin (or Neosporin) ointment at
bedtime. Follow your patient daily and modify therapy based on
the clinical response.
There is a less intensive approach that can be used if you
think your patient has a leukocytic infiltrate, but are still concerned
about possible infection. Here, use any fluoroquinolone or
aminoglycoside hourly until the patient is seen back the next day
to assess the clinical course. In either diagnostic circumstance,
(bacterial infection or leukocytic infiltration), improvement will
most always be evident, mainly because lens wear has been dis-
continued.
Nave practitioners who witness such improvement may
wrongly deduce that the lesion must have been an infective
process, and be glad they used an antibiotic. Once again, infiltrates
are very common, and bacterial keratitis is very rare.
The most appropriate therapeutic response to an immune/
inflammatory condition (e.g., a leukocytic/sterile infiltrate) is a
steroid. Since a small epithelial defect may or may not be present,
or clinical judgment may be wrong (if the lesion actually is an
early infectious disease process), we always prescribe an antibiotic/steroid
combination drug, such as Zylet, TobraDex, or generic
Maxitrol to treat these conditions. To this day, tobramycin remains
an excellent, broad spectrum bacterial antibiotic.
Prescribe the combination drug to be used q2h for two days,
then q.i.d. for four days (mainly to quiet the inflammation and
allow the eye to calm down).
Each doctor must evaluate each patienťs condition carefully
and prescribe with as much precision as possible. As stated at
the outset, treatment of contact lens-associated keratitis is rather
straightforward in most cases. In ambiguous cases, treat conservatively
until the diagnosis becomes clear. For perspective, we
have seen less than a handful of cases of microbial keratitis
between the two of us.
Contact Lens-Associated Keratitis
REVIEW OF OPTOMETRY JUNE 15, 200726A
well-known principle. No authoritative textbook recommends
the use of a prophylactic antibacterial agent
in such cases. As
clinicians, we do
not know why
the herpetic
corneal defect
does not invite
opportunistic
bacterial
pathogens; we
just know that
antibacterial
therapy is not
needed, unless
there is clear evidence
of concurrent bacterial infection.
Topical Viroptic (trifluridine, Monarch
Pharmaceutical), perhaps in conjunction with preservative-free
artificial tears, is the only therapeutic intervention
warranted for herpes simplex epithelial keratitis.
Oral antivirals, such as acyclovir (400mg five times
daily for seven days) can be used if there is trifluridine
resistance, or if the patient has developed an allergic
response to trifluridine.
Corneal Abrasions. Most such defects heal within a
day or two, regardless of any therapeutic maneuvers.
To our knowledge, no studies have prospectively followed
"no treatment" of abrasions, but it would be
interesting to know the absolute need for prophylactic
antibiotic use, which is standard practice in these situations.
We imagine the rate of infectious keratitis would
be very small. However, since antibiotics are safe, there
is no mandate to take unnecessary risks.
Conservative therapy with antibiotics has evolved
into the standard of care for corneal abrasions. There
are, however, circumstances--most notably delay in
seeking care--in which the abraded eye is considerably
inflamed. While fungal infection is always a rare possibility
if the traumatic agent was vegetative, 99.9% of
the time fungus is not a player.
That being said, we have occasionally used a shortacting
cycloplegic agent and a combination drug in
"hot" eyes with corneal abrasions. The steroid component
calms the tissues and thus potentiates corneal reepithelialization.
A further note for the fungal worriers
out there: if the delay in seeking care is only two to
four days, fungal involvement at this point is unlikely,
since fungi are usually slow growing and would take
many more days to proliferate to symptomatic propor-
tions.
Combination Drugs
Herpes simplex keratitis
Now, if the patient gives a history
of vegetative trauma, and reports
that the abrasion initially healed
over a day or two, but is now (perhaps
a week later) presenting with a
hot eye and stromal infiltrates, consider
fungal etiology. However, such
symptoms are still most likely associated
with a cell-mediated immune
response to the initial trauma rather
than a fungal infection. The salient
features of a fungal keratitis are:
* History of corneal injury (vegetative
matter)
* Slowly progressive
* Hypopyon in advanced cases
* Not very painful (relatively)
* Feathery border (hyphate-like)
* Slightly raised, dirty-white infil-
tration
* Satellite lesions
* Partial or complete ring
* Secondary anterior uveitis
For perspective, in our combined
50 years of intense clinical experience,
we have seen a grand total of
two cases of fungal infection following
corneal abrasion, both of
which were treated successfully.
If, however, the traumatic vector
of the corneal abrasion was inorganic,
and there is marked inflammation,
a combination product
could be considered. More conservatively,
use a pure antibiotic a day
or two, then if the traumatic keratoconjunctivitis
fails to subside or if
symptoms worsen, add a steroid.
Phlyctenular Keratoconjunctivitis
(PKC). Most usually seen in young
girls, this staphylococcal hypersensitivity
response commonly targets
the limbal tissues as one or two
raised, whitish lesions, which stain
lightly with fluorescein. Nothing
else looks like a phlyctenule.
While one would think staphylococcal
blepharitis would always be
evident, such is not empirically the
case. Certainly, if blepharitis is present,
initiate proper care, but first
treat the inflammatory keratoconjunctivitis.
When there is a staining
defect at the corneolimbus, a prophylactic
antibiotic is counterproductively
conservative.
The key clinical feature is the
inflammatory component--the eye
is red. Here, a combination product
is probably wise. Use a combination
drug every two hours for a day or
two, then q.i.d. for four to six days,
and then stop.
Staph. Marginal "Ulcers" (much
more appropriately called "peripheral
inflammatory epithelial
defects"). These are uncommon
events that have a similar pathophysiology
to PKC and sterile infiltrates.
In these cases, the staphylococcal
exotoxins begin to erode a
section of the peripheral corneal
epithelial tissues. The eye is red
with accentuation of a sector of
bulbar conjunctival inflammation
adjacent to the affected cornea. The
foci of compromised epithelium
REVIEW OF OPTOMETRY JUNE 15, 200728A
Infectious Ulcers vs. Sterile Infiltrates
ULCER
Rare
Usually painful
Tends to be central
Size of epithelial staining defect closely mirrors
the size of the underlying stromal lesion
Cells in anterior chamber
Generalized conjunctival injection
Usually solitary lesion
Possible tear lake debris
INFILTRATE
Common
Mild pain
Tends to be peripheral
Epithelial staining defect size relatively
small compared to underlying stromal
infiltrate
No cells (or minimal cells) in anterior
chamber
Sector skewed injection pattern
Can be multiple lesions
Clear tear lake
Is it an ulcer or an
infiltrate? At left is an
infectious ulcer. At
right is a sterile infil-
trate.
These classic, limbally expressed
phlyctenules were treated with Zylet
(q2h for two days; then q.i.d. for five
days) with quick resolution.
Fungal (fusarium) infection with stromal
infiltrate.
REVIEW OF OPTOMETRY JUNE 15, 2007 29A
stains brightly with fluorescein dye. There may be a few
cells in the anterior chamber. The epithelium is broken
down as a result of the underlying anterior stromal
inflammatory process, thus causing retrograde compromise
to the overlying epithelium.
Once this subepithelial inflammation is subdued by
the corticosteroid component in a combination drug,
re-epithelialization is potentiated. An antibiotic alone in
this case is almost worthless. While an antibiotic can
serve to protect against opportunistic bacterial potential,
it will do nothing to curb the inflammatory
process.
As with PKC, a combination product is perfectly
suited to address the inflammatory process while simultaneously
guarding the cornea against the possibility of
bacterial infection. Therapeutic management is as
described for PKC.
Keratoconjunctivitis Sicca (KCS). We have all seen
dry eye patients with slit lamp-observable, coarse SPK.
Also known as punctate epithelial erosions, SPK represents
a break in epithelial integrity that theoretically
provides a foothold for bacterial adherence and subsequent
penetration. Yet, antibiotic intervention is rarely,
if ever indicated.
Acknowledging the participation of inflammation in
the pathogenesis of many cases of dry eye-related SPK,
topical steroid and/or Restasis (cyclosporine, Allergan)
therapy is often employed (along with artificial tears,
etc.) in the successful management of KCS.
We have never read of an antibiotic role in the management
of KCS.
In summary, select a pure antibiotic when the clinical
picture is portrayed by evident mucopurulent discharge,
or there is evident (or high risk for) corneal infection.
Select a combination drug in the absence of the
above two findings when there is mild to moderate
epithelial compromise near the limbus along with considerable
conjunctival inflammation.
Select a pure steroid if the eye is red and the corneal
epithelium is intact. We might default to a combination
drug if the patient is a contact lens wearer, but such
would depend upon the individual situation.
We have discussed many exceptions to these general
guidelines. The primary purpose of this article is to
encourage the reader to limit the prescribing of an
antibiotic for the gamut of red eyes and recognize that
most red eyes are inflammatory in nature.
Most importantly, prescribe with precision! 
Combination Drugs
CALL FOR CLINICAL CONUNDRUMS
Got a problematic patient? Having difficulty
determining a diagnosis? Can't come to a
conclusion on course of therapy? Send your
clinical conundrums to Drs. Melton &
Thomas at: DrugGuide@jobson.com.
They'll publish your question--and their
answer--in next year's Clinical Guide to
Ophthalmic Drugs.
Peripheral anterior stromal infiltrates may or may not exhibit overlying epithelial compromise (as evidenced by positive fluorescein
staining). This contact lens wearer presented with a typical `infiltrate,' which was treated with Zylet (q2h for two days, then
q.i.d. for four more days).
Allergic conjunctivitis prompts many office patient encounters. New and modified
anti-allergy drugs provide patient-friendly dosing and over-the-counter availability.
ALLERGY DRUGSALLERGY DRUGS
O
ptometric physicians write
roughly equal numbers of
prescriptions for antiallergy
medicines as do our
surgical counterparts. This is
appropriate prescriptive
behavior, similar to the
observation that primary
care physicians write for
more allergy medicines
than specialty physicians.
Slowly but steadily, optometric
prescribing is
approaching a rational
and appropriate level.
New and Revised Drugs
The ocular allergy management
landscape has indeed changed in
2007. Alcon has released a higher
concentration (0.2%) of olopatadine,
marketed as Pataday. It is the
first topical antihistamine/mastcell
stabilizing drug to be
approved for once-daily dosing.
While once-daily instillation is
always a welcome dosing schedule,
it will be especially convenient
for contact lens wearers
because they can instill Pataday
a few minutes prior to insertion
of the lenses, and then enjoy all day
relief.
While the drug is not approved
for use with contact lenses, we see
no reason why any of the antiallergy
preparations cannot be
safely used with either disposable
contact lenses or RGP lenses.
Further news on the allergy front
is the transformation of ketotifen to
over-the-counter medication, which
has previously been the prescription
product Zaditor. Ketotifen is now
available OTC under two brand
names: Alaway (Bausch & Lomb),
REVIEW OF OPTOMETRY JUNE 15, 200730A
Ocular Allergy Medicine Profile
BRAND NAME GENERIC NAME MANUFACTURER PEDIATRIC USE BOTTLE SIZE(S) DOSING
Acute Care Products
Acular LS ketorolac tromethamine 0.4% Allergan 3 years 5ml, 10ml q.i.d.
Alaway (OTC) ketotifen fumarate 0.025% Bausch & Lomb 3 years 10ml b.i.d.
Alrex loteprednol etabonate 0.2% Bausch & Lomb 12 years 5ml, 10ml q.i.d.
Elestat epinastine HCl 0.05% Allergan 3 years 5ml b.i.d.
Emadine emedastine difumarate 0.05% Alcon 3 years 5ml q.i.d.
Optivar azelastine hydrochloride 0.05% MedPointe 3 years 6ml b.i.d.
Pataday olopatadine hydrochloride 0.2% Alcon 3 years 2.5ml q.d.
Patanol olopatadine hydrochloride 0.1% Alcon 3 years 5ml b.i.d.
Zaditor (OTC) ketotifen fumarate 0.025% Novartis 3 years 5ml b.i.d.
Chronic Care Products
Alamast pemirolast potassium 0.1% Vistakon Pharm. 3 years 10ml q.i.d./b.i.d.
Alocril nedocromil sodium 2% Allergan 3 years 5ml b.i.d.
Alomide lodoxamide tromethamine 0.1% Alcon 2 years 10ml q.i.d.
Crolom cromolyn sodium 4% Bausch & Lomb 4 years 10ml q.i.d.
Opticrom cromolyn sodium 4% Allergan 4 years 10ml q.i.d.
and Zaditor (Novartis Ophthalmics).
For patients who have no
issues with b.i.d. dosing, or
those who have no prescription
drug benefits,
these relatively inexpensive
OTC products
should nicely meet
their needs. Certainly,
they are vastly
preferred over
topical vaso-
constricting
products.
Allergic conjunctivitis is
a common condition
prompting office patient
encounters. Many of
these patients present
with true ocular allergy
as a result of environmental
allergen exposure.
Many others present with secondary
allergic symptoms because they
have subnormal tear film dysfunction.
The latter group of patients
express itchy eyes because their
impaired tear function does not
adequately dilute and/or wash away
environmental allergens. Indeed, a
large number of these patients presenting
with itching/burning eyes
simply have "dry eyes," and are
rendered asymptomatic with appropriate
intervention(s) for insufficient
tear film function. Therefore,
it is important that we first rule out
dry eye when patients present with
symptoms compatible with allergic
conjunctivitis.
If the history and examination
clearly yield a diagnosis of allergic
conjunctivitis, simply prescribe one
of these four antihistamine/mast cell
stabilizers b.i.d. p.r.n.:
Antihistamine/Mast Cell
Stabilizers
* Alaway (ketotifen, Bausch &
Lomb)
* Elestat (epinastine, Allergan)
* Optivar (azelastine, MedPointe)
* Pataday (olopatadine,
Alcon)
* Patanol (olopatadine,
Alcon)
* Zaditor (ketotifen,
Novartis)
All of these perform
well. The only two distinguishing
features are:
once-daily dosing of
Pataday; and over-thecounter
availability of
Alaway and Zaditor.
Prior to the advent of
these newer generation
antihistamines with
some mast cell stabilizing
properties, pure
antihistamines were the
workhorses in allergic
eye disease as well as in
the treatment of lid
myokymia (lid twitch).
These antihistamines
were Livostin (levocabastine,
Novartis) and Emadine
(emastadine, Alcon). As of
December 2004, Novartis
stopped production of
Livostin, so now Alcon's
Emadine is the sole representative
of this class.
For lid myokymia, we
generally prescribe
Emadine q.i.d. for one
week, then b.i.d. for one
to two weeks. We have
had nearly as good results with
antihistamine/mast cell stabilizing
agents, but prefer the pharmacologic
action of a pure antihistamine
in the setting of myokymia.
Some patients with ocular allergy
present with clinical inflammation
above and beyond symptomatic
itching. These patients are best
served by a topical steroid. Alrex
(loteprednol 0.2%, Bausch &
Lomb) or FML (fluorometholone
alcohol, Allergan) every two hours
for two days, then q.i.d. for a week,
then b.i.d. or once-daily for several
more days or weeks can be
enormously beneficial to
this subset of allergy
patients.
If the clinical expression
is more pronounced,
then consider Lotemax,
rather than Alrex or
FML. Since loteprednol
is extraordinarily safe relative
to the older ketone-based
steroids, we see no reason to be
timid with corticosteroid suppression
when patients need a steroid.
The February 2005 issue of
EyeWorld, a publication of the
American Society of Cataract
and Refractive Surgery, had a
special issue on ocular allergy.
We provide the following quotes
and commentaries on this topic,
and on other topics in the
remainder of this chapter:
"Clearly, it appears that topical
steroids do indeed have a role
in some patients with ocular allergy;
a treatment modality in the past
largely avoided by most for fear of
secondary steroid complications,"
says Stephen S. Lane, M.D.1
Mast Cell Stabilizers
Mast cell stabilizers have no
role in acute allergy expression.
These drugs have no active therapeutic
properties! They simply
chemotherapeutically make the
mast cell membrane stable in the
face of antigenic exposure, and
therefore prevent the subsequent
release of allergy-causing chemical
mediators.
There are two advanced formulations
of this drug class:
* Alamast (pemirolast, Vistakon
Pharmaceuticals)
* Alocril (nedocromil, Allergan).
Prescribe them q.i.d. for a week,
then b.i.d. p.r.n. We no longer use
the first generation products Crolom,
Opticrom and Alomide, since
these more advanced formulations
REVIEW OF OPTOMETRY JUNE 15, 2007 31A
Allergy Drugs
REVIEW OF OPTOMETRY JUNE 15, 200732A
have become available.
Again, for acute allergy
expression, try a steroid.
Mast cell stabilizers are
for long-term preventive
and maintenance therapy.
Says John D.
Sheppard, M.D.: "I can
get as much out of a
drop every other day of
Lotemax or Pred Forte
as I can four times a day
with Alamast."2
For patients with known allergy
triggers, such as cat exposure, mast
cell stabilizers can be taken q.i.d.
for one week prior to the anticipated
exposure to prevent or minimize
a subsequent allergic response.
Mast cell stabilizers, when used
appropriately, can virtually eliminate
the outbreak of allergic reactions.
These drugs work by
inhibiting the degranulation of mast
cells, preventing them from releasing
histamine and other allergy
mediators. They are completely safe
medications that can be used for
weeks or months without any significant
side effects. Since they are
preserved, there is a low risk of toxicity,
especially in patients with
compromised tear function.
Here's what the experts have to
say about using mast cell stabilizers
with contact lenses and for dry eye:
"Using mast cell stabilizers alone to
combat contact lens-associated
allergies is often a mistake, but
physicians still run into that and
other pitfalls associated with the
drug." (More on contact lenses and
allergies later.) "Another common
misuse of mast cell stabilizers is for
dry eye, simply because of a missed
diagnosis. The most common mistake
physicians make is to believe
the mast cell stabilizer is going to
work quickly for severe disease. In
fact, mast cell stabilizers are better
suited as a maintenance drug."2
Advise Against
Vasoconstrictors
Discourage patients from using
over-the-counter (OTC) anti-allergy
drugs that include vasoconstrictors.
In our experience, most patients
using OTC vasoconstrictor products
have dry eyes with low-grade,
secondary conjunctival hyperemia.
We strongly advise against the
use of any and all OTC vasoconstrictors
because their short duration
of action often encourages
multiple instillations. This, in turn,
may result in rebound conjunctival
hyperemia, and exacerbate the redness
they are trying to eliminate.3
"In the past, we have been limited
in our treatment of this frustrating
problem to vasoconstrictors,
decongestants, and antihistamines,"
Dr. Lane says.1
"While sometimes
helpful, these treatments are most
often unsatisfactory and in many
cases (especially the over-thecounter
medications) lead to toxicity
from either the agent or the
preservatives they contain."
We have for many years urged
patients not to use OTC vasoconstrictors
for their ocular surface
redness, be it from allergy or dry
eyes. The goal should be to prevent
red eyes from allergy and dryness,
not just to "whitewash" the eyes
when they become red.
Children with Ocular Allergy
Regarding allergic conjunctivitis
in children: "The single best morsel
of advice I can give to the parents
of an allergic child is to wash their
chilďs hands frequently. Children
just won't stop rubbing their itchy
eyes," Dr. Sheppard says.4
"So
many of the oral anti-allergy drugs
have a significant drying effect on
the eye. That just creates more
Cyclosporine for VKC Coming Soon?
In May, the FDA approved orphan drug designation for
Vekacia, a proprietary cationic emulsion of cyclosporine
A for the treatment of vernal keratoconjunctivitis (VKC)
in children. The drug is produced by Novagali Pharma,
of Evry, France.
In Phase III clinical trials, Vekacia reduced both signs
and symptoms of VKC, and the drug was safe and well
tolerated, the company says. Note that this is the same
drug as Restasis (cyclosporine, Allergan), but of a higher concentration--Restasis is
cyclosporine 0.05% whereas Vekacia is cyclosporine 0.1%.
Vekacia is the first drug intended specifically for treating VKC. Previous research has
found that cyclosporine A inhibits eosinophilic infiltration by interfering with the type IV
allergic reaction in the conjunctiva.1
Signs of edema, follicles, giant papillae and corneal
complications improved after one month of treatment with cyclosporine 0.1% administered
t.i.d.2
But the cationic oil-in-water emulsion vehicle, as used in Vekacia, resulted in
significantly (11-fold) improved corneal and conjunctival delivery compared with
cyclosporine 2% in an olive oil vehicle.3
We have not yet had the opportunity to try this therapy. In any case, we will continue to
use Lotemax or Pred Forte as first-line treatment to get VKC under control, and perhaps
use this new drug only if the the steroid therapy failed, or to maintain control once such
had been achieved by the steroid.
1. Fukushima A, Yamaguchi T, Ishida W, et al. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated
by type IV allergic reactions. Clin Experiment Ophthalmol 2006 May-Jun;34(4):347-53.
2. Fujishima H, Takano Y, Murat D, et al. 0.1% Cyclosporine eye drops for patients with vernal keratoconjunctivitis. ARVO
poster (5845/B408); May 10, 2007.
3. Lambert G, Rabinovich-Guilatt L. Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal
keratoconjuctivitis sicca (VKC). ARVO poster (2301/B999); May 07, 2007.
Limbal vernal conjunctivitis.
Allergy Drugs
problems in addition to the frequent
behavioral changes seen in
children taking antihistamines
orally," he says.
If a topical antihistamine/mast
cell stabilizer fails to achieve relief,
then certainly try a pulse dose
course of Lotemax every two hours
for four days; then use both Patanol
and Lotemax b.i.d. for a week. At
the end of this short pulse of corticosteroid,
the condition should be
sufficiently controlled such that the
antihistamine/mast cell stabilizer
alone can maintain asymptomatology
as long as necessary. With children,
use the least amount of
steroid the least amount of times to
accomplish the greatest good.
Contact Lenses and Ocular
Allergy
It is well known that contact lens
wearers are disproportionately
bothered by allergy. This begs the
question of safety and efficacy of
using Pataday, Zaditor, Optivar or
Elestat with contact lenses. No
problem. Just to be conservative,
have the patient instill the morning
drop a few minutes prior to insertion;
the afternoon drop can go
right on top of the contact lens.
To quell hyperacute allergic reactions,
use potent topical corticosteroids
(Lotemax, Inflamase Forte,
Vexol, fluorometholone acetate
0.1%, or prednisolone acetate 1%)
every hour or two for a day or two.
In these more marked expressions,
cold compresses can be immensely
helpful in restoring calm.
Once you've neutralized the
marked inflammatory response
using one of the potent corticosteroids,
then, if indicated, switch to
an appropriate anti-allergy medication
to continue to suppress any
chronic expression of disease.
What to do with an allergic contact
lens wearer in a case of severe
papillary conjunctivitis? "You really
need to crank out the big guns if
patients don't stop using contacts.
REVIEW OF OPTOMETRY JUNE 15, 200734A
Allergy Drugs
Pearls for Ocular Allergy
* The price of various popular anti-allergy eyedrops can vary considerably. We urge you
to have your staff consult two or three pharmacies near your office to get price quotes on
your ten most prescribed medicines. Trust us, you will be amazed--not just in how the
cost for the same medicine varies from pharmacy to pharmacy, but at the cost difference
between competitive products.
* Try getting your patients with dry eye complaints off oral antihistamines. They can
cause or exacerbate ocular surface dryness, which can be counterproductive to eye allergy
relief.
* Many patients who present to the eye doctor have concurrent allergic rhinitis and/or
allergic sinusitis. Many of these patients might achieve comparable or better relief from
their symptoms with the popular steroid nasal sprays than from the oral antihistamines.
* Antihistamine/mast cell-stabilizing eyedrops can render a therapeutic effect to allergic
rhinitis by virtue of their accessibility to these tissues via nasolacrimal drainage and local
distribution.
* Steroid nasal sprays rarely cause ocular side effects, but patients on high-dose pulmonary
inhaler delivery systems can, on occasion, experience ocular hypertension and/or
PSC cataracts from their use.
* Most q.i.d. allergy meds can maintain a good therapeutic effect at b.i.d. dosing following
a q.i.d. loading period of one to two weeks. We have also found that patients using
b.i.d. allergy medicines for a couple of weeks can often be maintained at q.d. dosing.
* Discourage patients from rubbing their itchy eyes. Rubbing causes mast cell degranulation,
which perpetuates the allergic cycle.
In other words, you should use a
steroid that really will reverse as
much as possible the underlying
pathology of the cobblestone or
severe papillary conjunctivitis. Once
the patient is stabilized and has a
fairly normal looking tarsus, iťs
fine to switch back to using the
mast cell stabilizer, with a gradual
steroid wean."2
We have advised the use of
steroids in these instances for years
and could not agree more!
"If you want the efficiency of an
anti-immunologic agent, one might
even consider very infrequent use of
the `big daddy'--the steroid--to
control swelling, vasodilation,
migration of eosinophils, and
release of granules from the mast
cell," Dr. Sheppard says. "That is
all accomplished by the topical
application of a steroid, which
might be done in the evening after
removing the contact lenses as
infrequently as every other day during
the peak of the allergy season
once the initial symptoms have been
controlled."2
He adds, "I think once a day, or
once every other day with the
tremendous activity you achieve
with a steroid, you are really creating
a continuous level of immunosuppression,
or down-regulation of
the allergic response. With the more
frequent use of the antihistamine
and multiaction topical anti-allergy
agents, you require the more frequent
application perhaps twice a
day. Even at every other day, we all
know we can accomplish quite a bit
with oral steroids once the initial
episode has been brought under
control as maintenance therapy."
Fortunately, most allergy expressions
can be controlled with a topical
antihistamine. When such
therapeutic intervention insufficiently
subdues the allergenic
expression, pulse dosing with Lotemax
can reduce the pathologic
expression below the antihistamine
efficacy threshold. An example of
pulse dosing in this context could
be every two hours for three days,
then q.i.d. for a week. Hopefully,
the steroid will have nicely subdued
the inflammatory response so that a
topical antihistamine/mast cell stabilizer
can keep the patient asymp-
tomatic.
Another approach to using
steroids like Lotemax was discussed
previously; that is, a drop every
morning (at least 10 minutes before
inserting contact lenses) and a second
drop after contact lenses are
removed in the evening. Such b.i.d.
dosing could supplement topical
antihistamine/mast cell stabilizers
during contact lens wear.
This approach could be modified
to just a drop of Lotemax near bedtime
for a few weeks if needed to
get these more challenging patients
through the worst of the allergy
season. As always, use the least
amount of medicine possible to provide
maximum patient care. Please
understand, we do not ever prescribe
steroids frivolously, but we
are not timid in our use of these
awesome drugs when needed.
In closing, dry eye is epidemic
and the most common cause of the
"itchy-burnies." True allergy is the
near-exclusive cause of isolated
itching. Cold compresses and refrigerated
eye drops can be helpful.
Most patients do very well with one
of the antihistamine/mast cell stabilizers.

1. Lane SS. As spring blossoms with allergy symptoms, consider
these treatment options. EyeWorld 2005 Feb:3.
2. Best strategies to treat CL users that have allergies.
EyeWorld 2005 Feb:43-44.
3. Soparkar CN, Wilhelmus KR, Koch DD, et al. Acute and
chronic conjunctivitis due to over-the-counter ophthalmic
decongestants. Arch Ophthalmol 1997 Jan;115(1):34-8.
4. Young M. To combat allergies in children, iťs avoidance,
then treatment. EyeWorld 2005 Feb 2005: 37.
REVIEW OF OPTOMETRY JUNE 15, 200736A
Ovaries and the Ocular Surface
There may be a unique expression of the itchy-dry eye that is associated with polycystic
ovary syndrome (PCOS), the most common endocrine abnormality in women of reproductive
age. PCOS afflicts approximately 4 million women in the U.S., and is generally characterized
by ovulation failure, hyperandrogenism, and polycystic ovaries.
Critical ocular clinical features include: conjunctival hyperemia; itching; dryness; excessive
mucous production; foreign body sensation; photophobia; burning; and contact lens
intolerance. These signs and symptoms tend to appear approximately three years following
the diagnosis of polycystic ovary disease.
While these signs and symptoms clearly overlap with dry eye and allergic eye disease,
"We suspect that the unusual coupling of itching and dryness is a distinct clinical entity
associated with hormonal imbalance, and we have designated this condition, the itchydry
eye associated syndrome (IDEA)," the authors write.1
This ovarian-associated syndrome
tends to respond poorly to traditional dry eye or allergic therapy, which can also be
a clue that the clinical presentation is not a typical case of dry eye and/or allergy.
"In conclusion, itchy-dry eye symptomatology in PCOS seems to be a distinct clinical
entity that shares many characteristics with dry eye and ocular allergic disease, but has
the unique feature of a concomitant endocrinopathy."1
1. Bonini S, Mantelli F, Moretti C, et al. Itchy-dry eye associated with polycystic ovary syndrome. Am J Ophthalmol 2007
May;143(5):763-771. Epub 2007 Mar 23.
Allergy Drugs
Severe papillary conjunctivitis.
REVIEW OF OPTOMETRY JUNE 15, 200738A
W
e are now at a point
where we have sufficient
topical medicines to
achieve "non-progression," or
"minimal acceptable progression"
in most patients with glaucoma. In
fact, one could argue that the
greater public good would be to
divert all glaucoma pharmaceutical
R&D funds into glaucoma detection
programs.
As there is only one notable
development in glaucoma medication
this year, we present an abbreviated,
"just the facts" chapter. For
those in a "catch-up mode," see
our web site (www.eyeupdate.com)
for further details on each of the
glaucoma drugs.
The prostaglandins
have truly captured the
hearts of optometrists
and ophthalmologists,
and for good reason. It is
amazing that one drop
per day of a highlydiluted
prostaglandin
can cause sufficient
cytoarchitectural remodeling
within the uveoscleral
tissues to enable a
30% reduction in IOP.
For balance and perspective,
for 25 years we
have had once-daily
beta-blockers that can
produce a 20 to 25% reduction in
IOP via aqueous production inhibition.
Thaťs impressive, as well. In
our experience, we have found that
target IOP can be reached and
maintained in +/-80% of glaucoma
patients with one or the other (or
both) of these two medicines.
Thaťs really pretty simple when
you think about it. Of course, the
most difficult challenge is getting
patients to faithfully use their medicines
as prescribed.
Xalatan (latanoprost, Pfizer)
should be stored under refrigeration
at the pharmacy. This is because
there remains some uncertainty
regarding its long-term (a year or
more) stability at room temperaThe
arsenal of glaucoma therapies is robust, with the addition of a preservative-free
prostaglandin. But, the question of when to initiate glaucoma therapy remains.
GLAUCOMAGLAUCOMA
Note the inferior erosion of the neuroretinal rim in
this case of advanced glaucoma. The patient was
asymptomatic to her superior total altitudinal visual
field defect.
Help Your Patients Get Their Drops
The attentive physician is aware that cost is a major determinant of compliance.1
There
are some patients who can afford Betimol (or a generic, non-selective beta-blocker), but
cannot afford a prostaglandin. Since the issue of cost may well be pivotal for some
patients, be wise in assessing your patients' abilities to be compliant with treatment from
a cost perspective. Keep in mind that every pharmaceutical company has an indigent
drug program that allows truly needy patients to receive glaucoma drugs at little or no
cost. We recommend that every optometrist and ophthalmologist obtain a complimentary
copy of the "Directory of Ophthalmic Pharmaceutical Assistance Programs for the
Medically Underserved." This directory is available upon request from:
Eye Care America
Public Service Programs
P.O. Box 429098
San Francisco, CA 94142-9098
(877) 887-6327
www.eyecareamerica.org
1. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995 May-Jun;26(3):
233-6.
Glaucoma
REVIEW OF OPTOMETRY JUNE 15, 2007 39A
ture. Once a patient receives
the Xalatan, it can be kept
on the nightstand or in any
other convenient place of
the patienťs choosing.
None of the glaucoma
medicines should be
stored in direct sunlight,
or in an enclosed place
where temperatures may
become excessively hot.
Travoprost has two
formulations: first-generation
Travatan (Alcon) and the newer,
updated BAK-free Travatan Z
(Alcon). (The "Z" is marketingspeak
for zero BAK). Both formulations
have demonstrated to perform
equally at reducing IOP. Given that
BAK has the potential to cause
epithelial toxicity, any effort to
decrease ocular surface exposure
is pharmacologically virtuous.
This is especially promising in
the setting of dry eye conditions.
Both formulations come
in 2.5ml and 5ml bottles.
Now that Travatan has been
upgraded to Travatan Z, we
anticipate that the latter will
be the exclusively prescribed version
of travoprost.
Time of prostaglandin instillation
should not be a concern. While the
prostaglandins are best suited for
evening instillation, the difference
in effect is very small. Since compliance
is a far greater issue, patients
should instill their prostaglandin
drops when it is most convenient
for them to do so.
In summary, the optometric profession
is perfectly positioned to
positively impact glaucoma care.
Glaucoma is most often diagnosed
during the course of routine eye
examinations. This provides us
with both great responsibility and
opportunity for early diagnosis and
appropriate intervention. For the
betterment of our respective communities,
we should redouble our
efforts to diagnose and manage
glaucoma within our practices. 
Topical Glaucoma Drugs
BRAND NAME GENERIC NAME MANUFACTURER CONCENTRATION BOTTLE SIZE
Beta Blockers
Betagan, and generic levobunolol hydrochloride Allergan 0.25% 5ml, 10ml
0.5% 2ml, 5ml, 10ml, 15ml
Betimol timolol hemihydrate Vistakon Pharm. 0.25% 2.5ml, 5ml, 10ml, 15ml
0.5% 2.5ml, 5ml, 10ml, 15ml
Betoptic-S betaxolol hydrochloride Alcon 0.25% 2.5ml, 5ml, 10ml, 15ml
Istalol timolol maleate Ista 0.5% 5ml
Timoptic, and generic timolol maleate Merck, and generic 0.25% unit-dose, 2.5ml, 5ml, 10ml, 15ml
0.5% unit-dose, 2.5ml, 5ml, 10ml, 15ml
Timoptic-XE, and generic timolol maleate Merck, and generic 0.25% 2.5ml, 5ml
0.5% 2.5ml, 5ml
Prostaglandin Analogs
Lumigan bimatoprost Allergan 0.03% 2.5ml, 5ml, 7.5ml
Travatan travoprost Alcon 0.004% 2.5ml, 5ml
Travatan Z travoprost Alcon 0.004% 2.5ml, 5ml
Xalatan latanoprost Pfizer 0.005% 2.5ml
Alpha Agonists
Alphagan P, brimonidine Allergan, 0.1%, 0.15%, 5ml, 10ml, 15ml
and generic brimonidine generic 0.2% 5ml, 10ml, 15ml
Iopidine apraclonidine Alcon 0.5% 5ml, 10ml
1% unit-dose
Carbonic Anhydrase Inhibitors
Azopt brinzolamide Alcon 1% 5ml, 10ml, 15ml
Trusopt dorzolamide Merck 2% 5ml, 10ml
Carbonic Anhydrase Inhibitor/Beta Blocker Combination
Cosopt dorzolamide/timolol Merck 2%/0.5% 5ml, 10ml
T
he new measures for Medicare's
Physician Quality
Reporting Initiative speak
directly to patient care in the setting
of macular degeneration. Measure
13 states that patients over age 50
with a diagnosis of age-related macular
degeneration should have at
least one antioxidant vitamin or
mineral supplement prescribed/recommended
within 12 months of
diagnosis. This clearly follows the
guidelines from the National Eye
Institute's Age-Related Eye Disease
Study (AREDS).1
These new Medicare guidelines
acknowledge what we have been
doing clinically for several years
now. In our practices, we routinely
recommend PreserVision gel caps
(Bausch & Lomb) b.i.d. for all nonsmokers,
and PreserVision Lutein
(Bausch & Lomb) b.i.d. for those
who smoke, or have a recent history
of smoking. AREDS demonstrated
that such therapeutic
supplementation slows the rate of
progression by about
25% in many
patients.2
While not
an ideally robust
intervention, it is the
most effective benefit
we can offer patients
with the dry/atrophic
form of age-related
macular degenera-
tion.
There is a newer,
simpler technique for
assessing the risk of
developing advanced
AMD. This comes as
a refinement from AREDS. The
important progression risk factors
are the presence of large drusen
(i.e., 125m or larger) and/or pigment
abnormalities. For reference, a
venule at the disc margin is about
125m in size. Regarding RPE pigmentary
changes, these changes are
either present or absent, and require
no quantification. The use of this
newer system for assessing risk of
advancement or progression is as
follows:3
Each eye is evaluated separately,
and the score for both eyes is combined.
One point is counted if large
drusen are present, and one point
for pigment change, for a possible
total score of 4 points for both eyes
combined. Patients with a score of
4 points have a 50% risk of developing
advanced AMD over five
years; 3 points a 25% chance; 2
points a 12% chance, and with a
score of 1, only a 3% chance.
While this system seems very simple,
it has been proven valid, and it
allows clinicians to easily assess
risk, which in turn enables us to
more knowledgeably counsel our
patients.
As a general guideline, we recommend
PreserVision to most of our
patients who display any significant
expression of age-related macular
degenerative changes. We also
encourage these patients to increase
their consumption of dark green
leafy vegetables. For those patients
on Coumadin (warfarin, BristolMyers
Squibb), we strongly encourage
them to consult with their
physicians prior to making such a
REVIEW OF OPTOMETRY JUNE 15, 200740A
Quality Reporting Guidelines for AMD
The 2007 Physician Quality Reporting Initiative (PQRI) guidelines can be seen at
www.cms.hhs.gov/PQRI. These 74 unique guidelines, issued by the Centers for Medicare
and Medicaid Services (CMS), cover all elements of medical care. The stated goal for
these guidelines is to achieve the clinical standards outlined therein 80% of the time.
Two of these standards are critical to the care of patients with macular degeneration:
Age-Related Macular Degeneration: Age-Related Eye Disease Study (AREDS)
Formulation Prescribed/Recommended
Description: Percentage of patients aged 50 years and older with a diagnosis of agerelated
macular degeneration who had the AREDS formulation prescribed/recommended
within 12 months.
Age-Related Macular Degeneration: Dilated Macular Examination
Description: Percentage of patients aged 50 years and older with a diagnosis of agerelated
macular degeneration who had a dilated macular examination performed which
included documentation of the presence or absence of macular thickening or hemorrhage
AND the level of macular degeneration severity during one or more office visits
within 12 months.
Drusen in dry AMD. Two major interventions for these
patients: smoking cessation and use of PreserVision.
AGE-RELATED MACULAR DEGENERATIONAGE-RELATED MACULAR DEGENERATION
REVIEW OF OPTOMETRY JUNE 15, 2007 41A
change in their diets, since the vitamin
K in these vegetables can alter
their coagulation profiles. Lutein
and vitamin K are both present in
dark green leafy vegetables, but
lutein supplements do not contain
vitamin K. Therefore, lutein supplements
are safe with regard to coagulation
function.
If patients with advanced
atrophic degenerative changes convert
to hemorrhagic (or exudative/
wet) forms of macular degeneration,
then a retinal specialist
should be consulted for an assessment
of the benefit of intravitreal
Lucentis (ranibizumab, Genentech
Inc.) or Avastin (bevacizumab,
Genentech Inc.) injections. 
1. Bressler NM, Bressler SB, Congdon NG, et al.; AgeRelated
Eye Disease Study Research Group. Potential public
health impact of Age-Related Eye Disease Study results:
AREDS report no. 11. Arch Ophthalmol 2003
Nov;121(11):1621-4.
2. Age-Related Eye Disease Study Research Group. A randomized,
placebo-controlled, clinical trial of high-dose supplementation
with vitamins C and E, beta carotene, and zinc
for age-related macular degeneration and vision loss: AREDS
report no. 8. Arch Ophthalmol 2001 Oct;119(10):1417-36.
3. Four-point scale developed to simplify AMD risk assessment.
Ocular Surgery News 2007 Jan 22.
AMD Update
Smoking is the leading cause of preventable morbidity and mortality
in industrialized countries.2
As health-care providers, we have,
at the very least, a supporting role in primary prevention of tobacco-related
disease. Since smoking also increases the risk of macular
degeneration and exacerbates the course of diabetes mellitus,
we have a fiduciary role as well in joining with our patienťs primary-care
physician to encourage smoking cessation.
(On a side note, we would do well to have our staff check the
blood pressure on our patients over 40 years old. As with glaucoma,
there is a huge population with undiagnosed systemic hypertension
out there. Offering blood pressure checks as part of our
spectrum of care would be an enormous service to our patients.)
Chantix (varenicline,
Pfizer) is new drug that aids
in smoking cessation. It is a
nicotinic acetylcholine receptor
agonist, and is also pharmacologically
able to block
nicotine receptor binding.
This dual action helps dampen
both cravings and withdrawal symptoms. There is also some
dulling of the sense of smoking satisfaction while on Chantix.
Interestingly, there are no contraindications to this drug.
Chantix was FDA-approved in May 2006, and may offer smokers
the best chance yet to stop smoking. Chantix is a 1mg tablet
that is taken twice daily for 12 to 24 weeks following a one-week,
lower-dose induction phase. In clinical trials, 44% of subjects
abstained entirely from smoking during the 12 weeks of therapy.3
At one year, however, the success rate is less than 25%. Still, this
drug appears to achieve the highest cure rates of any pharmacologic
intervention to date.
Every day in our practices, we encounter patients who smoke.
As part of our patient care, we inform them of the availability of
new drugs that may help them if they would like to stop smoking.
Every day, we write the name "Chantix" on the back of our business
cards, give them to our smoking patients, and ask them to
discuss this new medication with their doctor on their next visit.
This is at the very least a nudge, and a step in the right direction.
For more information, go to www.chantix.com.
Another smoking cessation drug, Zyban (bupropion, GlaxoSmithKline)
was the first non-nicotine medication approved by the
FDA. Bupropion is perhaps better known by its original brand
name Wellbutrin, which is indicated for the treatment of depression.
Zyban/Wellbutrin works by inhibiting neural re-uptake of
dopamine and/or norepinephrine. The dopamine relieves craving;
the norepinephrine dampens nicotine withdrawal. Other commonly
employed approaches are nicotine replacement products, such as
skin patches, gums, nasal sprays and lozenges.
In summary, there are a number of pharmacologic agents available
to help our patients stop smoking. Our role is to be at least
casually knowledgeable about these interventions and to make our
smoking patients aware of new medicines as they come to market.
We encourage you to write the name Chantix on your business
card with the active hope that your patients will discuss it with
their physicians. Iťs good for your patients, and iťs just another
example of how optometrists can work as a team with other
members of our medical community to promote public health.
1. Moradi P, Thornton J, Edwards R, et al. Teenagers' perceptions of blindness related to
smoking: a novel message to a vulnerable group. Br J Ophthalmol 2007 May;91(5):605-7.
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United
States, 2000. JAMA 2004 Mar 10;291(10):1238-45.
3. Jorenby DE, Hays JT, Rigotti NA, et al.; Varenicline Phase 3 Study Group. Efficacy of
varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or
sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA
2006 Jul 5;296(1):56-63.
Wet, or hemorrhagic, AMD is best
prevented. But newer anti-VEGF drugs,
such as Avastin or Lucentis, can be
enormously beneficial for some patients.
"Eye-care practitioners, particularly optometrists, should
consider asking their adolescent patients whether they
smoke and provide advice on quitting to smokers."
-- British Journal of Ophthalmology, May 20071
A New Drug to Combat Cigarette Smoking
REVIEW OF OPTOMETRY JUNE 15, 200742A
T
here are two key points to
consider in current dry eye
therapy. First, punctal occlusion
seems to be underutilized.
Second, many doctors are initiating
therapy with Restasis (cyclosporine,
Allergan) before doing an "inflammation
detection" trial with a topical
corticosteroid. It is very difficult
to identify which patients will benefit
from cyclosporine and which
will not. Since a valid therapeutic
trial with cyclosporine can take as
long as three to four months, we
suggest the following initial
approach: Have the patient try
Lotemax (loteprednol 0.5%,
Bausch & Lomb) q.i.d. in the more
symptomatic eye for two weeks. If
the patient derives considerable
benefit, this strongly indicates that
inflammation is playing a clinically
significant role in that individuaľs
tear film dysfunction. At this point,
consider a trial of Restasis, or simply
continue Lotemax b.i.d. for
another month or two, then once
daily for a few months. This latter
option is much more cost effective.
Punctal Plugs
Punctal plugs do seem to be helpful
for many patients. For those
patients with moderate tear volume,
plugs can offer significant
symptomatic relief. However, if the
tear volume is scant, the main benefit
that plugs may offer is prolonging
the residence time of artificial
tears. Patients with scant lacrimal
lakes must use the recommended
artificial tear frequently (at least
every four hours); otherwise, tear
film stagnation caused by the punctal
plugs may concentrate proinflammatory
cytokines in the tear
film and actually exacerbate signs
and symptoms of dry eye. In such
cases, pulse dosing with Lotemax
q.i.d. for two weeks, then b.i.d. for
two weeks, along with frequent
instillation of artificial tears, should
be accomplished prior to plugging
the inferior puncta.
Since plug extrusion is a common
problem, always attempt to
insert the largest-size plug that can
be fitted. Use punctal gauge devices
to determine the optimal size.
Anti-inflammatory Therapy
Photophobic, painful and
injected eyes are inflamed. These
eyes almost invariably respond to
pulse dosing with Lotemax or FML
q.i.d. for two to four weeks, along
with frequent use of artificial tears.
While most patients with ocular
surface drying do not overtly manifest
inflammation, they may still
benefit significantly from immunosuppressive
intervention. This can
be accomplished with Lotemax,
Restasis, or perhaps with a severalmonths'
course of orally-adminisThe
vast majority of patients with dry eye woefully underutilize their artificial tears.
In this section, we offer an algorithm for engaging the dry eye patient.
THE DYSFUNCTIONAL
TEAR FILM
THE DYSFUNCTIONAL
TEAR FILM
A Prescription Artificial Tear
Focus Laboratories, Inc., based in North Little Rock, Ark., has developed an
artificial tear product whose most unique distinguishing feature is that it is
available by prescription only.
FreshKote sterile ophthalmic solution contains polyvinyl pyrrolidone 2.0%,
polyvinyl alcohol 0.9% (87% hydrolyzed), and polyvinyl alcohol 1.8% (99%
hydrolyzed), along with Amisol clear, and other buffers and electrolytes. The
manufacturer states that, "This patented blending enhances ocular surface
wettability, delays tear evaporation, assists ocular surface healing, and treats
all three layers of the tear film." It is preserved with disodium edetate dihydrate
and Polixetonium, and comes in a 15ml bottle. The approximate retail price is $30.
We are in the process of our own informal clinical trials, and will be able to offer our
clinical perspectives in next year's Drug Guide. For more information, visit the FreshKote
web site at www.freshkote.com. As we have said over the years, it is important to try all
new products in the clinical setting so that a consensus of professional opinion can evolve
quickly and appropriate decisions can be made to maximize health care.
REVIEW OF OPTOMETRY JUNE 15, 2007 43A
tered doxycycline or omega-3 essential
fatty acid supplementation.
Biomedical research has confirmed
that inflammation plays a
clinically significant role in many
patients with precorneal tear film
dysfunction. Generally speaking,
the greater the signs and symptoms,
the more success we have had with
topical inflammation therapy. Note
that concurrent use of artificial
tears is always implemented.
If you have decided upon a therapeutic
trial with an anti-inflammatory
medication, there are two ways
to proceed: with either topical corticosteroids
or topical cyclosporine.
Since corticosteroids (we usually
use Lotemax) have an onset of
action much faster than cyclosporine,
initiate anti-inflammatory therapy
q.i.d. with the steroids. When
the patient returns in a month, the
clinical response (or lack thereof)
will indicate whether this patienťs
dry eye is characterized by clinically
significant inflammation.
If the steroid trial was significantly
beneficial, two choices are
available: Either continue the
Lotemax b.i.d. for one month then
taper to once-daily for a month or
two (along with artificial tears), or
continue the Lotemax b.i.d. for a
month along with Restasis b.i.d.
Since it usually takes Restasis at
least a month to render a meaningful
effect (and two to four months
in many patients), front-loading
with the steroid quantitatively
diminishes the expression of inflammation
and seems to potentiate the
therapeutic effect of Restasis.
A drop or two of Lotemax for
two to four months should be both
safe and effective in virtually all
patients.
Our experience has shown that
some patients do well for months,
then become acutely symptomatic.
Pulsing with Lotemax q.i.d. for one
week, then b.i.d. for a week or two
can regain control for many more
months. Since Restasis is a slowonset
drug, it is not suitable for
pulse dosing. If the time period
between acute symptomatic exacerbation
becomes too short, then
either continue the Lotemax at b.i.d
tapered to q.d. after a week or two,
or Restasis at b.i.d. for several
months. Periodically stop the medicine
to assess how the patient does
without it. Always attempt to use
the least amount of medicine to
care for the patient. 
Dry Eye
Therapeutic Options for Dry Eye
THERAPY
Mild Options: ˇ Artificial tears alone, and/or
* Punctal plugs alone, and/or
* Omega-3 fatty acid supplementation
Moderate Options: ˇ Artificial tears used frequently
* Gel formulation at bedtime
* Punctal plugs
* Omega-3 fatty acid supplementation
* Restasis trial for 3-6 months
Severe Options: ˇ More viscous, preservative-free artificial
tears used frequently
* Lotemax q.i.d. for 1 week, then b.i.d. for a
month (to observe for significant inflammatory
component)
* Long-term Restasis if Lotemax brought
relief
* Oral doxycycline; 100mg/day for 2 weeks,
then 50mg/day for 6 months
* Omega-3 fatty acid supplementation for 3
to 6 months
* Punctal plugs, once the above measures
have been in effect for a month or two
* Moisture shields or moisture goggles
Each therapeutic intervention can influence (hopefully positively) the effects of other therapeutic
maneuvers. For example, punctal plugs may enable the patient to decrease the
frequency of artificial tear instillation. Omega-3 fatty acid supplementation may likewise
diminish the need for artificial tears. Of course, if a patient were to be highly compliant
with artificial tears, then perhaps the need for punctal plugs and/or omega-3 supplementation
would be precluded. There is a dynamic state of flux in managing dry eye disease.
Each intervention may complement other maneuvers, so a precise clinical algorithm for
managing dry eye disease is impossible because of the enormous individual variability of
both the disease process as well as response to therapy.
USAGE
Two of these may
be needed concur-
rently.
Two or three of
these interventions
may be necessary
to achieve control.
Since punctal
plugs have the
potential to concentrate
inflammatory
cytokines, try
first to get the ocular
surface tissues
at least partially
rejuvenated prior
to plugs. Of course,
intervention is
highly variable
among patients.
Punctal plugs are an underutilized
modality in the care of patients with
insufficient tear volume.
A
s part of our lectures, we are privileged to
answer many hundreds of questions and offer
our perspectives on a wide range of issues germane
to optometric practice. Here, we share a number
of these clinical pearls and pointers. Some are strictly
informative. Others are meant to stimulate thought.
But all are focused on helping you sharpen your skills.
* Synechia in the context of anterior uveitis can be
problematic as it can increase IOP, and resulting in
anisocoria in bright or dim light. Inability to dilate the
pupil in the
future (for
example, in the
patient with
acute onset of
flashes and/or
floaters) could
preclude the
needed clinical
evaluation.
Most of the
time, synechiae
can be broken
during the presenting
visit. But
in some cases,
the synechial
breakage occurs
after a few days
of appropriate
treatment. We
normally treat
synechiae with a
couple of drops
of 1% tropicamide
along with
a couple of drops of 2.5% phenylephrine (sometimes
10%, if needed) at presentation.
If the synechiae break within an hour or so, fine; if
not, and the IOP is below 30mm Hg, then we prescribe
Pred Forte (not a generic substitution, primarily
because of the potential for a poorer quality product)
to be used hourly while awake, along with either
0.25% scopolamine or 5% homatropine three to four
times each day. Very rarely is there a need to prescribe
FML ophthalmic ointment at bedtime.
We usually find the synechiae have broken by the
patienťs first follow-up in three to five days, but there
are those recalcitrant cases in which the synechiae
remain permanently. While certainly not desirable, as
long as the IOP remains normal, it is an acceptable situ-
ation.
In our experience, it is usually the patient who has
been misdiagnosed prior to coming to definitive care,
the undertreated patient (either through mismanagement
or poor patient compliance), and the patient who
simply thought, "it would get better," and delays seeking
care who have the truly stubborn synechia that can
result in a permanently fixed pupil.
* Acne rosacea is most commonly expressed between
the ages of 30 and 50, mostly afflicting white patients.
The mainstay of therapy is an oral tetracycline antibiThomas
Jefferson was the prototypical "lifelong learner," and we should emulate his
constant pursuit of knowledge. To that end, here we offer pearls that we've learned.
CLINICAL PEARLS IN
PATIENT CARE
CLINICAL PEARLS IN
PATIENT CARE
REVIEW OF OPTOMETRY JUNE 15, 200746A
Synechiae commonly result from delay
in seeking care and suboptimal dosing
of a cycloplegic drug and/or topical
corticosteroid.
After four days of proper care, the
synechiae are all broken.
* The National Rosacea Society has available an
excellent brochure, "Coping with Rosacea." Copies
can be obtained by e-mailing rosaceas@aol.com. Visit
the web site at www.rosacea.org. We have found that
many, if not most, of our patients with posterior
blepharitis also have rosacea. This brochure has
helped us more comprehensively manage our
patients with this disease.
47AREVIEW OF OPTOMETRY JUNE 15, 2007
otic, such as doxycycline or minocycline, for several
months to a year or so, depending upon the clinical
response. There are patients who only present with
ocular signs--exemplified by evident telangiectatic vessels
on the top portion of the eyelids (best seen on the
inferior eyelid), tear film dysfunction, possibly corneal
neovascularization, and multiple, subtle paralimbal
infiltrates--and show no evidence of cutaneous disease;
i.e., true ocular rosacea.
Rarely, younger children can be afflicted. If the child
is less than 10 years of age, oral erythromycin at a
dosage of 20mg/kg has been shown to be highly thera-
peutic.1
But when dosing patients older than 10 years,
we generally use doxycycline or minocycline at 50mg
per day. Topical corticosteroid eyedrops, such as Lotemax,
may also be needed to help quiet any expression
of corneal inflammatory disease. Be aware that rosacea
can present at almost any age, and a portion of acne
rosacea patients will not have any skin disease to help
elucidate the diagnosis.
Oral therapy commonly needs to be maintained for
several months, with pulse dosing of a topical steroid if
there are any flare-ups. Artificial tears are routinely
employed to manage any associated keratoconjunctivitis
sicca.
* Patients with lattice degeneration of the retina are
at risk for subsequent retinal tears or breaks that could
lead to detachment if not treated at the time of the rent.
However, this risk is less than 1%, and so patient reassurance,
not fear, should be given. Obviously, the
patient should be thoroughly educated regarding the
symptoms of a retinal tear, break or detachment, and
the chart so documented.
On the "glass is half-empty" side of the equation,
one-third of patients who have a retinal detachment
also have lattice degeneration.
* It is definitely time to do better than just record a
cup-to-disc (C/D) ratio. We challenge you to never
again write down just a C/D ratio, but to include an
accurate description of what you see on clinical examination.
Some examples follow:
"0.6 C/D with central, shallow cup"
"0.7 C/D with erosion of the superior temporal rim"
"0.5 C/D with deep central cup and uniform pink
neuroretinal rim"
"0.4 C/D with temporal pallor"
Such characterizations are not as important with
small cups, unless the optic nerve is small. Jost Jonas,
M.D., a well respected expert on the optic nerve, states
that in routine practice, the clinician conduct a quick,
crude estimate of whether the disc in question is average-sized
(medium), smaller-than-average, or larger-
than-average.2
Many times, a cup is not precisely 0.6 or 0.7, but
may be more accurately quantified as 0.65. Such wonderful
attention to detail is yet another indication of
astute attentiveness to the anatomy of the optic nerve
head.
Too many optometrists and ophthalmologists do a
surprisingly poor job of truly characterizing the optic
nerve head. Leťs work together to raise the bar and set
a new standard of documenting the optic nerve.
Remember, among the three million Americans who
have glaucoma, as many as half of them remain undiagnosed.
We feel very strongly that if we all discipline
ourselves to critically analyze and characterize the optic
nerve head, such diagnostic oversight would largely
cease.
Clinical Pearls
* Receiving benefits paid for with your federal tax dollars
isn't quite as good as free, but iťs about as close as it gets.
Your National Eye Institute in Bethesda, Md., has a very nice
array of excellent patient education brochures available at no
cost upon your electronic request. These are all well written and
they are "politically correct" regarding
optometry vis--vis ophthalmology. Topics
are wide ranging from commonplace to
esoteric. We urge you to peruse
the web site, www.nei.nih.gov, to
see the available offerings. Most
of the informational pieces can
be ordered in packets of 50 on a
monthly basis, as needed. In glaucoma,
for example, the NEI has
brochures for people "at risk" and
for people "with glaucoma." Iťs good to have both pamphlets
available for your patients.
* These will cost you, but ophthalmology/optometric journals
have enormous potential for your lifelong professional
growth. Thomas Jefferson was the prototypical "lifelong learner,"
and we should emulate his constant pursuit of knowledge. While
most of us receive optometric literature, precious few of us draw
upon other ophthalmic literature on a monthly basis. We subscribe
to five ophthalmology journals, and the knowledge gleaned
has enormously benefited our clinical care. We strongly recommend
you choose at least one of the journals available via
www.ophsource.com. Iťs an investment with lasting dividends.
* Finally (and this is completely free!), visit our web site,
www.eyeupdate.com, for practical, clinically-oriented information
that we think you will find helpful in your day-to-day practices.
ˇ Follow patients with ischemic central retinal vein
occlusion (CRVO) monthly for the first six months. On
each visit, look carefully for neovascularization of the
iris, do a quick four-mirror gonioscopic examination to
look for angle neovascularization, and check the IOP
prior to dilation. If neovascularization of the iris (NVI),
of the disk (NVD), or elsewhere (NVE) develops, then
send the patient to a retinologist for panretinal photocoagulation.
After the first six months, check CRVO
patients quarterly for one year, then annually.
* Culturing is a common topic, yet uncommonly
indicated. Culturing should, however, be considered in
the following situations:
­ Severe purulent conjunctivitis
­ Chronic or recurrent conjunctivitis unresponsive to
standard therapy
­ Neonatal ocular infection
­ Central or moderate-sized corneal ulcers
­ Postoperative ocular infection
­ High suspicion for fungal keratitis
* When dilating patients with potentially occludable
iridocorneal angles, it is probably best to dilate them in
the morning with either Paremyd (0.25% tropicamide/
1% hydroxyamphetamine hydrobromide,
Akorn) or 0.5% tropicamide. It
is relatively easy to reverse the dilatory
effects of these two medicines, and
should angle-closure occur, there
would be plenty of time to move
through the management protocol and
arrange for a YAG laser photoiridotomy.
It is vitally important to challenge
these narrow angles in a
controlled clinical setting. A worst-case
scenario would be for one of your
patients to be on a remote vacation
and have a spontaneous occlusion. This could prove to
be a litigiously unhappy patient because the doctor
failed to diagnose a potentially blinding condition in a
proactively timely manner.
REVIEW OF OPTOMETRY JUNE 15, 200748A
* Erectile dysfunction and the drugs used to treat this condition
have generated considerable discussion in the lay and
professional press. The prime issue as it relates to vision is: Do
these drugs pose a risk to vision via anterior ischemic optic neuropathy
(AION)? The answer is, "maybe," but the consensus opinion
is that while there is an association, these drugs are probably
not causal.
In the October 2005
American Journal of
Ophthalmology, Frederick
Fraunfelder, M.D.,
states, "Since millions
have taken these medications
with risk factors
for AION, this may
be an expected coincidence...
Postmarketing
surveillance ... has
produced no data to
date which confirms a
`certain' relationship between AION and erectile dysfunction med-
ications."1
An editorial in that same issue states, "Most, but not all, of
these patients had underlying anatomic or vascular risk factors
for development of NAION, including: small C/D ratio (crowded
disk), age over 50, diabetes, hypertension, coronary artery disease,
hyperlipidemia, and smoking."2
They go on to say, "a possible
association [exists] ... but a causal relationship has not been
established conclusively."
ED medicines are basically phosphodiesterase-5 (PDF)
inhibitors. Phosphodiesterase-6 is found in the retina and is
thought to partially explain some of the visual phenomena occasionally
experienced by patients taking one of the drugs in this
class. These include Viagra (sildenafil, Pfizer), Levitra (vardenafil,
Bayer), and Cialis (tadalafil, Lily ICOS). Since nonarteritic anterior
ischemic optic neuropathy is seen most commonly in patients
with small optic nerve heads and/or minimal cupping, i.e., "the
disk at risk," the optometrisťs role is to be aware of all of their
patients' medicines. Any patient using PDF inhibitors should be
advised of the possible risk of AION if they have "high risk optic
nerve heads."
With more than 200 million ED drug prescriptions written for
(and presumably used by) more than 23 million men, we would
think any true cause-and-effect relationship would be evident. We
can't imagine that it will be much longer until definitive data are
available to seal this question.
1. Fraunfelder FW. Visual side effects associated with erectile dysfunction agents. Am J
Ophthalmol 2005 Oct;140(4):723-4.
2. Lee AG, Newman NJ. Erectile dysfunction drugs and nonarteritic anterior ischemic
optic neuropathy. Am J Ophthalmol 2005 Oct;140(4):707-8.
ED Drugs and AION: Still a `Maybe'
A swollen optic disc, surrounded
by multiple flame-shaped hemorrhages,
is characteristic of NAION.
* The four-mirror goniolens is a workhorse in our practices.
Its exclusive virtue is its usefulness
for examining the iridocorneal
angle, most always related
to glaucoma assessment. Only
topical anesthesia is needed, and
the tear film serves as the interface solution. It is quick, efficient,
and patient-friendly.
REVIEW OF OPTOMETRY JUNE 15, 2007 49A
* High-sensitivity (hs) C-reactive protein (hs-CRP),
like erythrocyte sedimentation rate (ESR), is a nonspecific
barometer of system inflammation. Both of these
tests are blood derived and therefore require venipuncture
to collect samples for laboratory analysis. The
results of the tests can be obtained within a few hours
at almost any medical diagnostic laboratory.
CRP has both acute and chronic implications.
Optometrists use CRP almost exclusively in the diagnostic
workup of patients suspected of having giant cell
arteritis (GCA) as a companion test with ESR. The
CRP test typically elevates more rapidly in response to
inflammation and decreases more rapidly in response to
oral steroid therapy. The normal threshold within the
context of GCA is less than 2.45mg/L.
As for CRP's role in chronic disease, it can be a helpful
indicator of risk for cardiovascular disease. The following
information from our hospital laboratory
succinctly describes the role of hs-CRP in cardiovascular
risk assessment:
"CRP is a nonspecific marker of inflammation, and
a variety of conditions may cause elevated levels. CRP
values above 8.0mg/L are associated with clinical
inflammation.
"The cardiovascular risk profile may not apply to
patients with other known sources of inflammation. hsCRP
interpretation for cardiac risk is based on `quintiles
of risk.' The recommended quintiles are as follows:
Quintile 1 Lowest risk 0.1 - 0.6mg/L
Quintile 2 Low risk 0.7 - 1.1mg/L
Quintile 3 Moderate risk 1.2 - 1.9mg/L
Quintile 4 High risk 2.0 - 3.8mg/L
Quintile 5 Highest risk 3.9 - 15.0mg/L
"Patients with elevated hs-CRP concentrations are
more likely to develop stroke, myocardial infarction,
and severe peripheral vascular disease. Simultaneous
measurement of hs-CRP and lipids predict future vascular
risk better than lipid measurements alone. In
women, hs-CRP concentrations may be influenced by
hormonal status."
Clinical Pearls
* Uncommonly, a patient will present with
foreign body sensation resulting from a tarsoconjunctival
concretion that has eroded
through the overlying conjunctival epithelium.
(Such a concretion is composed of hyaline-like
material, and is not calcific in origin.) The
microerosion resulting from the protruding concretion
is readily observed with fluorescein
staining upon eyelid eversion. Any erosion that
has symptomatically eroded will preferentially
stain with sodium fluorescein dye.
Removing the lesion is rather straightforward.
Just instill a drop or two of proparacaine
or Fluress (fluorescein/benoxinate, Akorn). Also,
instilling a drop of 2.5% phenylephrine can be
useful to minimize the potential for a microbleed,
as these occasionally occur in concretion
removal.
Then use a "golf club spud," or other instrument
of your choice, and begin gently picking
away at the erosion site until the firm concretion
dislodges.
The concretion invariably comes out as a
single chunk. Some minor bleeding may occur,
but this quickly stops once the tarsal conjunctiva
is reapposed to the globe.
Following the procedure, consider instilling a
drop or two of antibiotic solution, or a small
amount of antibiotic ointment. Follow-up care is
simply PRN.
Example of eroding, symptomatic
aggregates of concretions, which
must be removed to bring relief and
comfort to the patient.
Use a needle to remove a
symptomatic eroding concretion.
When removing concretions, microbleeds
are common. They can be
reduced somewhat by pretreatment
with 2.5% phenylephrine.
The removed concretion is seen here
affixed to the cotton swab.
50A
* Diagnosing glaucoma in highly myopic (10D to 18D) individuals can
be rather challenging. It has been shown that the major anatomic weakness
in highly myopic patients is lamina cribrosa thinning, not thinning of
the retinal nerve fiber layer. Therefore, "OCT, CSLO, and GDx are not
useful to discriminate nonglaucomatous and glaucomatous subjects that
have high myopia."3
Furthermore, "clinicians often must rely on an examination
of the optic disc in order to diagnose glaucoma in high myopes,"
and, "the contour of the retinal vessels on the disc is often the sole indicator
of the surface topography." Therefore, "clinicians must assume each
highly myopic optic disc to be glaucomatous until proven otherwise."
In addition, "the optic disc in highly myopic eyes is oval, elongated, and
obliquely oriented to a significantly greater degree than in any other
group. The cup is also remarkably shallow." So, "evaluating the parapapillary
atrophy in myopia will not assist in the diagnosis of glaucoma."4
Hopefully, these perspectives will help guide your diagnostic decisions in
the setting of myopia.
* In patients with 7th facial nerve palsy (Belľs palsy), or any condition
resulting in incomplete blink or eyelid closure, always determine whether
Belľs reflex is intact. With forceful orbicularis eye closure, the eye(s)
should reflexively roll up and out within the orbit.
The way to assess the presence of absence of the Belľs reflex is to have
the patient look down, then use your thumbs to raise and pin the upper
lids to the superior orbital rim. Then, while the patient is looking in primary
gaze, ask that s/he forcefully attempt to close his/her eyes. If the Belľs
reflex is intact, the eyes will roll up and out; if absent, they will remain in
primary gaze. There is much less risk of corneal desiccation with an intact
reflex. If the reflex is absent, more aggressive lubrication may be needed to
protect against ocular surface drying.
REVIEW OF OPTOMETRY JUNE 15, 2007
Clinical Pearls
* Many people with macular degeneration also take Coumadin (warfarin,
Bristol-Myers Squibb) for anticoagulation. Most are keenly aware
that dark green, leafy vegetables should be avoided because of their vitamin
K content. This can be perceived as a concern by the patient when we
recommended a product containing lutein, since many patients also understand
this substance is found abundantly in dark green, leafy vegetables.
Certainly, it is a justifiable concern, so we need to explain to these patients
that while both vitamin K and lutein have many common sources, the latter
does not affect the INR (coagulability profile).
When patients present with symptoms compatible with posterior vitreous
detachment (PVD)--such as sudden onset of flashes, floaters, cloud,
curtain, and/or a spider-web appearance in their vision--give careful biomicroscopic
attention to the retrolenticular anterior vitreous (Berger's
space). Very often (but not always) if there is an associated retinal tear or
break, red blood cells (RBCs) and/or debris will be evident in this portion
of the vitreous cavity. This "tobacco dust" or "paprika" appearance
(known formally as Shaffer's sign), commands an exhaustive examination
of the peripheral retina. In evaluating Berger's space, a critical step is to
compare the fellow eye so as not to be misled by baseline non-RPE, nonRBC
debris that may occasionally be seen in normal vitreous. As a general
rule, in most eye conditions, it is wise to compare the fellow eye.
ˇ "One third of conclusions in major medical journals
are later found to be inaccurate,"reveals the
January 2007 American Journal of Ophthalmology.5
This is interesting--and disconcerting--to say the least.
* A word of perspective to those who have acquired
the Optos Instrument: While it is good technology
(similar to the glaucoma scanning devices), it is not
comprehensive in its diagnostic ability.
There are several circumstances that come to mind
in which either a magnified stereoscopic view or a
thorough peripheral examination is indicated. Three
such instances are when assessing for: an optic nerve
head or a retinal lesion; early diabetic retinopathy; or a
symptomatic posterior vitreous detachment. It may be
best in these special circumstances to pharmacologically
dilate the pupil, and carefully study the "at risk"
tissues.
* Drugs to treat diaphoresis (excessive sweating) are
commonly anticholinergics. Recently, we had an
emmetropic 15-year-old white female present with
recent onset accommodative difficulty. We questioned
her about the time of onset, and reviewed her medical
history. As it turned out, her focusing problem began
around the same time she had started on an antidiaphoretic
drug. A quick look in the reference text,
Drug-Induced Ocular Side Effects (5th ed., Butterworth
Heinemann, 2000), clearly states that accommodative
difficulty, especially in younger people, is seen
with use of cyclobenzaprine (Flexeril, McNeil). Use of
temporary reading glasses and a nice letter of explanation
to her physician were the key components of her
care.
The pearl here is threefold: Be an attentive investigator;
have good reference texts readily available; and
communicate with your patients' physicians.
* Regarding drug side effects, "clusters of case
reports suggesting an adverse ocular reaction are frequently
the first and only signal that such a problem
could be occurring."5
It is important, then, that when you encounter what
you deem a reportable drug side effect, that you contact
both of the following agencies: FDA MedWatch
(www.fda.gov/medwatch/index.html), and the National
Registry of Drug Induced Ocular Side-Effects
(www.eyedrugregistry.com or http://piodr.sterling.net).
* In multiple sclerosis patients, "the earlier the [betainterferon]
treatment is started, the better the outcome
appears to be," according to the November/December
2006 issue of EyeNet. In some cases the, "apparent disconnect
between MRI findings and physical disability
may be just a matter of time lag." The currently available
beta-interferons (Avonex, Betaseron and Rebif),
"can't reverse the damage already caused by the disease,
but they can help reduce the frequency of attacks
and slow the rate of future disability."
Our overview: When a patient presents with optic
neuritis, an MRI should be accomplished within one to
three days, and a neurological consult should scheduled
for a day or two after the MRI is done. If the MRI is
positive for demyelinating disease, the patient and neurologist
should have a thorough discussion regarding
immediate treatment with IV methylprednisolone and
subsequent long-term treatment with a systemic antiMS
agent. The O.D. can, and should, play an intimate
role in facilitating the above maneuvers through the
healthcare system. For more information, see our web
site, www.eyeupdate.com. 
Amiodarone, the O.D., and the Cardiologist
* Amiodarone (Cordarone, Wyeth-Ayerst) universally causes
a verticillate deposit in the corneal epithelium, which can, on
rare occasions, slightly decrease vision. However, this drug
also has the potential to cause an optic neuropathy. This highly
infrequent ocular
side effect is seen
bilaterally, since it is
thought to be a
response to the
systemic medicine.
The optic neuropathy
presents as a
papillitis, and can
occasionally be
confused with anterior
ischemic optic
neuropathy. The
time between the
patient starting amiodarone and the time of expression of optic
neuropathy is variable with no consistent pattern. Furthermore,
there is no relationship to dosage. After stopping the amiodarone,
some patients improve; others do not.
Medicolegally, a "causal" relationship has been established
between amiodarone usage and the development of optic neuropathy.
However, scientifically, the relationship between the two
is, "probably causal." The role of the optometrist is "advisor and
educator" to cardiologists regarding the potential for amiodaroneassociated
optic neuropathy. The key is to educate cardiologists
to seek optometric consultation for their patients on amiodarone
who develop vision problems.
Verticillate deposit in the corneal
epithelium caused by amiodarone.
REVIEW OF OPTOMETRY JUNE 15, 200752A
REVIEW OF OPTOMETRY JUNE 15, 2007 53A
1. Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: longterm
treatment with systemic antibiotics. Am J Ophthalmol
2006 Nov;142(5):816-21.
2. Jonas JB, Papastathopoulos K. Ophthalmoscopic measurement
of the optic disc. Ophthalmology 1995 Jul;102(7):1102-
6.
3. Melo GB, Libera RD, Barbosa AS, et al. Comparison of
optic disk and retinal nerve fiber layer thickness in nonglaucomatous
and glaucomatous patients with high myopia. Am J
Ophthalmol 2006 Nov;142(5):858-60.
4. Budde WM. Glaucoma or myopia? Glaucoma Today 2006
Sep/Oct;5:23-6.
5. Fraunfelder FW, Fraunfelder FT. Scientific challenges in
postmarketing surveillance of ocular adverse drug reactions.
Am J Ophthalmol 2007 Jan;143(1):145-149.
Clinical Pearls
It is hard to imagine in this highly enlightened age that a new ophthalmic
diagnostic entity would be "discovered," for surely giant
fornix syndrome has existed for decades, or even centuries. But,
such appears to be the case, and we experienced it firsthand.
Diagnostic Data
When a 76-year-old white male presented with a left red eye
and severe purulent discharge of five days duration, we presumed
that removing the discharge (which took 10 cotton swabs!) followed
by a few days of Vigamox (moxifloxacin, Alcon) would cure
it. Wrong! When the patient returned three days later, he looked
very much the same as he had initially (see image).
Diagnosis
Very fortuitously for both patient and doctor, the August 2004
issue of Ophthalmology had arrived and contained an article that
depicted this patienťs symptoms with near-divine intonation. The
article, by G.E. Rose, described twelve patients who had giant
fornix syndrome. From this article, we learned these patients
demonstrated "copious amount of thick, purulent debris and a yellow
coagulum lodged in the depths of the upper fornix--this
debris universally culturing Staphylococcus aureus." Dr. Rose
found that, "the condition settled rapidly on appropriate systemic
antibiotics [ciprofloxacin or ofloxacin], intensive topical antibiotics,
and high-dose potent steroids."
Management
In light of the above study, we started this gentleman on
Augmentin (amoxicillin/clavulanate potassium, GlaxoSmithKline)
875mg b.i.d., continued him on Vigamox hourly, added Lotemax
(loteprednol 0.5%, Bausch & Lomb) q2 hours, and urged him to
continue his use of warm soaks. In three days, the patienťs condition
showed considerable improvement, and he had complete resolution
five days later. We stressed to the patient the need for
meticulous eyelid hygiene, and instructed him to return immediately
should he experience any recurrence of symptoms.
Giant fornix syndrome is a unique clinical entity that requires a
unique clinical approach. Patients with this condition are typically
over age 75, and are likely to have excessively large recesses to
their superior cul-de-sacs. This allows sequestration of a thick
coagulum-harboring staph reservoir. Initially, this condition may
require daily follow-up or every-other-day follow-up so that the
superior fornix can be swept. We use sterile cotton swabs coated
with TobraDex (tobramycin/dexamethasone, Alcon) ointment to
accomplish this. Should the patient have a history of penicillin
allergy, we prescribe Levaquin (levofloxacin, Ortho-McNeil) 500mg
once daily for one to two weeks; otherwise, we prefer Augmentin
875mg b.i.d. for the same length of time. TobraDex ointment is
instilled at bedtime for the first week, then the patient may use
just GenTeal Gel (Novartis) for two more weeks, depending upon
the presence or expression of toxic epithelial keratitis.
In more recalcitrant or recurring cases, daily use of an antibiotic/steroid
such as Zylet (loteprednol/tobramycin, Bausch & Lomb)
b.i.d. to q.i.d. for a month or two may be required. Instruct the
patient to meticulously clean the eyelids using one of the newer lid
scrub products, such as SteriLid eyelid cleaner (Advanced Vision
Research). It is a good idea to demonstrate the technique in the
office for the patient and/or the caregiver.
When encountering an older patient with copious, cream-colored,
purulent discharge, consider the diagnosis of giant fornix
syndrome, particularly if the condition responds poorly to conventional
topical antibiotic therapy.
Rose GE. The giant fornix syndrome: an unrecognized cause of chronic, relapsing, grossly
purulent conjunctivitis. Ophthalmology 2004 Aug;111(8):1539-45.
CALL FOR CLINICAL CONUNDRUMS
Got a problematic patient? Having difficulty determining a
diagnosis? Can't come to a conclusion on course of
therapy? Send your clinical conundrums to Drs. Melton &
Thomas at DrugGuide@jobson.com. They'll publish your
question--and their answer--in next year's Clinical Guide to
Ophthalmic Drugs.
Giant Fornix Syndrome: A `New' Clinical Entity
It took 10 cotton swabs to remove all the purulent discharge
for this patient with `giant fornix syndrome.'
REVIEW OF OPTOMETRY JUNE 15, 200754A
Here, an expert pediatric ophthalmologist provides some very practical, down-toearth
clinical pearls on how to handle both pediatric patients and their parents.
PEDIATRIC PEARLSPEDIATRIC PEARLS
O
ur good friend and colleague,
Sandra M. Brown, M.D., is an
outstanding pediatric ophthalmologist
who offers the following
insights regarding pediatric eye care. It
is always a breath of fresh air to glean
wisdom from expert, "in-thetrenches,"
subspecialists. We thank Dr.
Brown for her willingness to share
these very helpful clinical insights with
us and you.
* Treating blunt trauma (without
serious eyelid edema) in an upset child.
First, forget the slit lamp. Use the
direct ophthalmoscope as a side illumination
source; it gives broader and
more even illumination than a muscle
light, without bright Purkinje reflexes.
You can see hyphemas and pupil irregularities
easily. You can treat traumatic
iritis empirically; although in children, this improves
rapidly and spontaneously without treatment. Check
for a red reflex since you've got the ophthalmoscope in
your hand.
Have the parent hold the child in a "soothing" position
in the exam chair. Let the child do his or her own
eye opening; don't touch the chilďs face. Be reasonable
about a dilated exam. If you think it is essential, do
what you are compelled to do; otherwise, skip it.
* Treating blunt trauma with serious eyelid edema.
Put on gloves to get a good grip on the eyelids. Place
the child flat on his or her back (chair laid back), and
have your technician/office assistant (NOT a parent)
hold the chilďs head. For toddlers, keep the child on
the parenťs lap and lean them both back; put the parent
in charge of the arms, torso and legs. Skip the anesthetic.
You may get just a glimpse of a rolling eyeball,
but this should allow you to answer the most critical
question: open globe--yes or no?
* Children with elevated IOP. Children can tolerate
moderately elevated IOP for weeks, so it is better to
presume the IOP is not dangerously elevated than get
into a major battle with the child in order to measure
it. When the child is upset, the IOP will be spuriously
elevated, anyway.
Pediatric pearl #9: Sit squirmy children in the parenťs lap.
Pediatric pearl #9a: One squirmy child at a time!
* Treating the child with a suspected corneal abrasion. When
you suspect a corneal abrasion, put the anesthetic in the eye first.
This can turn a screaming, thrashing kid into a both-eyes-open,
whimpering one. However, if the child already has the eye open,
don't put anything in the eye until you have completed your
assessment, or you will quickly be regarded as THE ENEMY.
ˇ Keeping the child with an eye injury quiet. Have
the parent sedate the child with any safe preparation on
hand at home that is known to make him or her sleepy.
Children's cold and cough medications often work
well, particularly Benadryl, if it is available. Have the
parent dose per the medication's instructions, according
to the chilďs body weight.
Older kids are often content to lie on the couch and
watch TV or DVDs. Video games and hand-held game
devices should not be allowed because they encourage
jerky eye movements. Be specific that the child is not to
play outdoors at all, nor to roughhouse indoors with
siblings or friends. Younger children find being still for
a lengthy period of time is very difficult. Better to let
them play gently on the floor than to force them to stay
in bed. Hospitalization is required for truly uncontrollable
children with hyphemas. More often this decision
is reached the next day when the parents report an
inability to comply with activity limitation at home.
* Getting oral medications "down the hatch." Some
medications, such as prednisone, taste quite nasty in
liquid form. Try to order concentrated solutions so that
the volume is small, and tell the parent(s) to mix the
medication with straight Hershey's Chocolate Syrup in
a larger spoon.
* Mulch attacks. As mulch has become an increasingly
frequent playground material, more kids are getting
ocular surface abrasions from falling or getting
mulch thrown in their eyes. Mulch tends to stick, so
look hard and deep in the inferior fornix, and be sure
to flip the upper lid(s). Particularly if you note fine vertical
abrasion lines, assume there is mulch under the
Pediatric Pearls
REVIEW OF OPTOMETRY JUNE 15, 2007 55A
* Hyphema management. To quiet the eye and decrease the
risk of bleeding, have a potent steroid, such as Pred Forte,
instilled six to eight times a day. Prescribe at a higher frequency
if you think Mom or Dad is likely to miss a dose or two, or will
have trouble instilling the drops in a squirmy chilďs eye.
Prescribe a long-acting cycloplegic drop such as atropine,
scopolamine or 5% homatropine for use once daily at bedtime.
Stress to the parent that only Tylenol (or generic acetaminophen)
should be given for pain. No NSAIDs (naprosyn, ibuprofen
or aspirin, etc.) should be used because any of these could
potentiate bleeding.
If the child is of African, Mediterranean or Middle Eastern
descent, have labs drawn to rule out sickle cell trait. These children
can have greater problems with rebleeding, are more likely
to have an elevated IOP with a small hyphema, and cannot tolerate
elevated IOP as it causes intravascular RBC sludging and
ocular ischemia. Sickle trait is widely distributed and a negative
family history for hemoglobinopathies is not sufficient evidence. If
the child is positive for sickle trait, the need for accurate serial
IOP measurements is greatly increased; in the worst-case scenario
this may mean sequential brief general anesthesias. Topical
or oral carbonic anhydrase inhibitors are contraindicated in cases
of sickle cell.
A hyphema is typically treated with cycloplegia and a
topical steroid, such as Lotemax.
* Tips for managing the parent(s) of an upset child. If both
parents are present, and one parent is crying or anxious, even a
mildly injured child may react frenetically or even hysterically in
response to that parent. Address both parents and say something
like, "I know this is frightening and upsetting to you. We will do
everything we can to take care of Joey, but to do so, we
absolutely must look at his eye. Children quickly pick up on the
vibes their parents send, and of course you are very worried. It
might help if you (addressing the upset parent) step out of the
room for just a minute." This will cause one of two things to happen:
the upset parent will leave the room (rarely); or (more often)
the upset parent will get it together, and (usually) the child will
become calmer, as well. Regardless of the parents' reactions, it is
important to validate their emotions as "reasonable under the cir-
cumstances."
If only one parent is present, this parent MUST be present with
the child at all times to prevent any claims of battery. Note that
torso bruising related to the original incident may precipitate a
report of battery if the parent is not allowed to remain with the
child, hears blood-curdling shrieks from the exam room, and presumes
the bruising was caused by the staff handling the child
too roughly.
If the child is particularly tough to control, you can motivate
the parent to help more by saying, "keep him still or he may
rebleed and possibly go blind," or, "he'll have to be in the hospital
for three or four days." Sometimes drastic situations call for dramatic
threats!
Except in cases in which the condition/injury is very mild, the
child is older and more cooperative, and the parents are quite
reliable, it is a good idea to schedule a one-day follow-up examination
to see how the behavior management is going.
upper lid(s) until proven otherwise. Fortunately, the dark brown
color of the mulch is easy to see. Often, parents won't know of a
particular mulch injury, but they may report the child came home
from school or daycare, "with a red eye." If you specifically ask,
you may learn there is mulch in the play areas.
I don't know why mulch gets thrown more often than sand; it
just does. Perhaps it is because most parents have had lots of
occasions to instruct their children not to throw sand, but since
mulch is relatively new on the scene, they may not have had as
many occasions to specifically instruct their children not to throw
mulch!
* Here is another pediatric pearl we've gleaned: Herpes simplex
keratitis (HSK) in children is bilateral in about 25% of cases,
according to a small retrospective study.1
As in adults, recurrence
was seen in about half of these patients, and these recurrent
episodes tended to occur within two years of the initial episode.
No eye with epithelial keratitis alone developed stromal keratitis,
but half of those with combined epithelial and stromal keratitis at
presentation later developed stromal keratitis. Lastly, about half
of these children developed a residual corneal opacity.
The study found oral acyclovir to be useful during acute therapy.
Our recommended dosage would be 200mg to 400mg (based
on the chilďs weight) five times daily for one week. A liquid formulation
of acyclovir is also available as an oral suspension in a
concentration of 200mg/5ml (i.e., one teaspoon). 
1. Chong EM, Wilhelmus KR, Matoba AY, et al. Herpes simplex virus keratitis in children. Am J Ophthalmol
2004 Sep;138(3):474-5.
Adenoviral conjunctivitis, especially epidemic keratoconjunctivitis
(EKC), can cause significant discomfort
and inconvenience to patients. While the
diagnosis of EKC is most usually a very straightforward
clinical diagnosis, there are patients whose
presentation poses a diagnostic dilemma.
The RPS Adeno Detector (Rapid Pathogen
Screening, Inc.) is a simple, in-office, non-invasive
device/procedure that can provide highly sensitive
and specific results in about 10 minutes. The
optometrist simply purchases one or more kits at
the cost of about $25, and can then provide hospital
laboratory-quality diagnostic services conveniently
in the office. For more information, consult
their web site: www.rps-tests.com.
Pediatric Pearls
REVIEW OF OPTOMETRY JUNE 15, 200756A
CALL FOR CLINICAL
CONUNDRUMS
Got a problematic patient?
Having difficulty determining
a diagnosis? Can't come to a
conclusion on course of
therapy? Send your clinical
conundrums to Drs. Melton &
Thomas at:
DrugGuide@jobson.com.
They'll publish your
question--and their answer
--in next year's Clinical
Guide to Ophthalmic Drugs.
When the Pharmacy is Out of the Prescribed Medication
We have, from time to time, encountered patients with herpetic eye disease, acute
uveitis, keratitis, and other severe (or potentially severe) eye conditions for which the
patients' pharmacies were either out of, or did not stock, the medicines we pre-
scribed.
Frequently, the pharmacist will tell the patient he can order the drug and have it for
the patient in a day or two. This may not be compatible with optimum care--in fact,
it usually is not.
Therefore, we provide the patient with proactive instructions to accompany the
prescription(s) in these special conditions. You can simply print several of these
adjunctive instruction notices on plain paper, cut them into prescription pad-sized
squares, and staple them directly to the prescription as needed. In many cases, this
"extra mile" measure significantly enhances patient care.
Here is a sample of the notice we use:
THIS MEDICATION IS URGENTLY NEEDED!
If your pharmacy does not have this drug available, please help direct the patient
to a pharmacy that can provide it to them so that therapy can begin right away.
­ Thank you
In-Office Adenoviral Test